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Soil-dwelling Streptomyces bacteria are known for their ability to produce biologically 
active compounds such as antimicrobial, immunosuppressant, antifungal and 
anticancer drugs. S. nogalater is the producer of nogalamycin, a potential anticancer 
drug exhibiting high cytotoxicity and activity against human topoisomerases I and II. 
Nogalamycin is an anthracycline polyketide comprising a four-ring aromatic backbone, 
a neutral deoxy sugar at C7, and an amino sugar attached via an O–C bond at C1 and a 
C–C bond between C2 and C5´´. This kind of attachment of the amino sugar is unusual 
thus making the structure of the compound highly interesting. The sugar is also 
associated with the biological activity of nogalamycin, as it facilitates binding to DNA. 
Furthermore, the sugar moieties of anthracyclines are often crucial for their biological 
activity. Together the interesting attachment of the amino sugar and the general 
reliance of polyketides on the sugar moieties for bioactivity have made the study of the 
biosynthesis of nogalamycin attractive.  
The sugar moieties are typically attached by glycosyltransferases, which use two 
substrates: the donor and the acceptor. The literature review of the thesis is focused on 
the glycosylation of polyketides and the possibilities to alter their glycosylation 
patterns. 
My own thesis work revolves around the biosynthesis of nogalamycin. We have 
elucidated the individual steps that lead to its rather unique structure. We reconstructed 
the whole biosynthetic pathway in the heterologous host S. albus using a cosmid and a 
plasmid. In the process, we were able to isolate new compounds when the cosmid, 
which contains the majority of the nogalamycin gene cluster, was expressed alone in 
the heterologous host. The new compounds included true intermediates of the pathway 
as well as metabolites, which were most likely altered by the endogenous enzymes of 
the host. The biological activity of the most interesting new products was tested against 
human topoisomerases I and II, and they were found to exhibit such activities.  
The heterologous expression system facilitated the generation of mutants with 
inactivated biosynthetic genes. In that process, we were able to identify the functions 
of the glycosyltransferases SnogE and SnogD, solve the structure of SnogD, discover a 
novel C1-hydroxylase system comprising SnoaW and SnoaL2, and establish that the 
two homologous non-heme α-ketoglutarate and Fe2+ dependent enzymes SnoK and 
SnoN catalyze atypical reactions on the pathway. We demonstrated that SnoK was 
responsible for the formation of the additional C–C bond, whereas SnoN is an 
epimerase. A combination of in vivo and in vitro techniques was utilized to unravel the 
details of these enzymes. Protein crystallography gave us an important means to 
understand the mechanisms. Furthermore, the solved structures serve as platforms for 





Maaperässä esiintyvät Streptomyces-suvun bakteerit tunnetaan niiden kyvystä tuottaa 
biologisesti aktiivisia yhdisteitä. Nogalamysiini on potentiaalinen syöpälääke, joka on 
solumyrkyllinen ja aktiivinen ihmisen topoisomeraasi I:tä ja II:ta vastaan. S. nogalater 
-kanta tuottaa sitä. Nogalamysiini on antrasykliinipolyketidi, joka koostuu 
nelirenkaisesta aromaattisesta rungosta ja siihen C7-asemaan liittyneestä neutraalista 
sokerista sekä aminosokerista, joka on liittynyt sekä O–C-sidoksella asemaan C1 että 
C–C-sidoksella C2- ja C5´´-aseman välillä. Yhdisteen rakenne on hyvin 
mielenkiintoinen, sillä aminosokeri on kiinnittynyt hyvin epätyypillisellä tavalla ja on 
omalta osaltaan vastuussa nogalamysiinin biologisesta aktiivisuudesta, sillä se auttaa 
molekyylin sitoutumisessa DNA:han. Myös yleisellä tasolla sokeriosat ovat usein 
vastuussa polyketidien biologisesta aktiivisuudesta. Yhdessä rakenteen epätavallisuus 
sekä sokeriosien tärkeys ovat tehneet nogalamysiinin tutkimisesta olennaista.     
Sokeriosien kiinnittämisestä vastaa tyypillisesti sokerinsiirtäjäentsyymi glykosyyli-
transferaasi. Tämä entsyymi käyttää substraatteinaan kahta molekyyliä, aktivoitua 
sokeria ja vastaanottajamolekyyliä, johon sokeri liitetään. Työni kirjallisuuskatsaus 
keskittyy sokerien liittämiseen polyketideihin sekä mahdollisuuksiin muuttaa näitä 
sokerointimalleja. 
Omat tutkimustulokseni liittyvät nogalamysiinin biosynteesiin, jonka yksittäisiä 
askeleita olemme tutkineet selvittääksemme, mistä yhdisteen lähes ainutlaatuinen 
rakenne johtuu. Siirsimme nogalamysiinin biosynteesistä vastaavan geeniklusterin 
heterologiseen isäntään, S. albukseen, kosmidin ja plasmidin avulla. Kun siirsimme 
isäntäkantaan ainoastaan kosmidin, joka sisälsi suurimman osan klusterista, mutta ei 
kaikkia geenejä, havaitsimme kannan tuottavan uusia yhdisteitä. Työssä mittasimme 
uusien yhdisteiden bioaktiivisuuden ihmisen topoisomeraaseja I:tä ja II:ta vastaan, ja 
niissä huomattiin olevan aktiivisuutta. 
Biosynteesiin liittyvien geenien ilmentäminen heterologisessa isännässä mahdollisti 
inaktivointimutanttien teon. Työn aikana pystyimme selvittämään kahden sokerin-
siirtäjäentsyymin, SnogE:n ja SnogD:n, toimintaa sekä SnogD:n rakenteen. Lisäksi 
löysimme uudenlaisen C1-aseman hydroksylaatiosysteemin, joka koostuu SnoaW:stä 
ja SnoaL2:sta, sekä kaksi homologista hemitöntä α-ketoglutaraatti- ja rauta2+-
riippuvaista entsyymiä: SnoK:n ja SnoN:n. Osoitimme, että SnoK on vastuussa 
epätyypillisen hiili–hiilisidoksen muodostumisesta, kun taas SnoN on epimeraasi. 
Entsyymien toiminnan yksityiskohtien selvittämiseksi käytimme sekä in vivo- että in 
vitro -tekniikoita. Proteiinikristallografian avulla selvitimme kolmen entsyymin 
kolmiulotteiset rakenteet, joiden avulla pystyimme ymmärtämään entsyymien 






AAT-fold Aspartate aminotransferase fold 
ABTS 2, 2′-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) 
ATP Adenosine triphosphate 
CO2 Carbon dioxide 
CoA Coenzyme A 
COSY  Correlation spectroscopy 
dTDP Thymidine diphosphate 
dUDP 2´-deoxyuridine-5´-diphosphate  
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
ESI-MS Electrospray ionization mass spectrometry 
Fe2+/ Fe(II) Iron (2+) 
GFOR Glucose-fructose oxidoreductase fold 
GT Glycosyltransferase 
HMBC  Heteronuclear multiple-bond correlation spectroscopy 
HPLC High performance liquid chromatography 
HRMS High resolution mass spectrometry 
HRP Horseradish peroxidase 
HSQC Heteronuclear single-quantum correlation spectroscopy 
HSQCDE Heteronuclear single-quantum and distortionless enhancement 
correlation  




NADH Nicotinamide adenine dinucleotide, reduced 
NADPH Nicotinamide adenine dinucleotide phosphate, reduced 
NDP Nucleoside diphosphate 
NMP Nucleoside monophosphate 
NTP Nucleoside triphosphate 
NMR Nuclear magnetic resonance 
NOESY Nuclear Overhauser effect spectroscopy 
OD600 Optical density at 600 nm 
PBS Phosphate-buffered saline 
PKS Polyketide synthase 
PLP Pyridoxal phosphate 
SAM S-adenosylmethionine 
SDR Short chain alcohol dehydrogenase 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SN1 Unimolecular nucleophilic substitution 
SN2 Bimolecular nucleophilic substitution 
SNi Nucleophilic internal substitution 
TLC Thin layer chromatography 
TOCSY Total correlation spectroscopy 
UDP Uridine diphosphate 
UV/Vis Ultraviolet/visible light 
wt Wild type 
α-KG Alpha-ketoglutarate/alpha-oxoglutarate 
Amino Acid Abbreviations 
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AMINO ACID ABBREVIATIONS 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 







Natural products are an interesting research topic because of their broad diversity both 
in their chemical structures as well as in their biological functions. Even with the 
advances made in modern organic chemistry, natural products cannot be replaced. The 
complex structures of natural products continue to inspire synthetic and analytical 
chemists. Natural products are an important source for human medicine, they work as 
potential biological probes, and there are still many to be discovered (Walsh and 
Fischbach, 2010). Significant producers of natural products are the soil-dwelling 
Gram-positive Streptomyces bacteria (Kieser et al., 2000). In addition to the 
compounds found in nature, substantial effort is being made to alter the chemical 
structures of natural products, so that they would work better as drugs.  
In the literature review, the focus is on polyketides, which are synthetized by 
polyketide synthases (PKSs). Three different types of PKSs are known, and they can 
be further divided into subtypes. They act either as modules or iteratively. A 
commonality with all the systems is their resemblance with fatty acid synthesis, where 
simple precursors are processed in successive decarboxylative condensation reactions 
(Khosla et al., 1999).  
Polyketides are often decorated with sugar moieties, which are attached by 
glycosyltransferases (GT) that use two substrates: the acceptor substrate, aglycone 
(derived from Greek: a: without and glycone: sweet), and the donor substrate, which 
donates the sugar moiety to be attached. There is a huge variety of aglyca and sugars in 
nature (Elshahawi et al., 2015).  
In many cases, carbohydrate moieties play a critical role in the biological activities of 
the compounds (Weymouth-Wilson, 1997). They facilitate the attachment of the 
compound to its target and may affect the stability as well as change the solubility 
properties of the compounds, which is an important factor in drug design (De Bryun et 
al., 2015). Additional carbohydrates have even been used in synthetic drugs to increase 
solubility (Williams et al., 2013). The carbohydrate moieties are typically attached via 
an O-, C-, N-, or S-glycosidic bond to the backbone, the most prevalent being the O-
glycosylation. The sugar moieties go through various modifications, such as 
dehydration, isomerization, and group transfers. Most modifications happen prior to 
the attachment, but modifications may also occur after the glycosylation event 
(Thibodeaux et al., 2008). One facile way to diversify natural products is to focus on 
altering the sugar moieties, their amount and/or their properties.  This is because the 
biological activity of compounds often relies on them, and because the sugar-
modifying enzymes from different pathways share structural and functional aspects, 




The focus of my experimental work is on nogalamycin (Fig. 1), an aromatic polyketide 
belonging to the anthracyclines made by type II PKS. In these metabolites, the 
aglycone onto which the sugar moieties are attached is a tetracyclic polyphenolic 
anthraquinone (Metsä-Ketelä et al., 2008). One of the sugar moieties of nogalamycin is 
attached in a very atypical manner, as the amino sugar is not only attached by the 
canonical O-glycosylation between the C1´´ and C1 positions but also via a C–C bond 
between C5´´ and C2. Although the substructure is not entirely unique in nature 
(Kawai et al., 1987; Searle et al., 1991; 2003; Ubukata et al., 1991; 1993a–b), it is the 
only one studied in detail with regard to its biosynthesis (Beinker et al., 2006; 
Grocholski et al., 2010; Kantola et al., 2000; Shao et al., 2015; Siitonen et al., 2012a; 
2012b; 2016; Sultana et al., 2004; Torkkell et al., 1997; 2001; Ylihonko et al., 1996) 
In this work, the late stage tailoring steps in nogalamycin biosynthesis were elucidated 
in detail and now it is understood where the special features of this compound 
originate. Firstly, prior to the attachment of the amino sugar, the aglycone is 
hydroxylated at position C1 by a novel two-component cofactorless monooxygenase 
system SnoaW/SnoaL2 (Siitonen et al., 2012a). Secondly, we identified and solved the 
crystal structure of the SnogD GT responsible for the transfer of the amino sugar, 
whereas the SnogE GT was shown to catalyze the transfer of the neutral sugar 
(Claesson et al., 2012; Siitonen et al., 2012b). Thirdly, we demonstrated that the C5´´–
C2 bond is formed by SnoK and that an unexpected epimerization of the C4´´ position 














2. LITERATURE REVIEW 
Natural products containing carbohydrate moieties are chemically diverse, not only 
because there are hundreds of different sugar moieties, but also because the aglyca onto 
which the sugar moieties are attached vary significantly. Furthermore, sugar moieties 
are found in most of the various classes of natural products (Elshahawi et al., 2015). 
The sugars are derived from the common carbohydrates of primary metabolism, but 
typically undergo a range of unusual modifications. Carbohydrate moieties attached to 
natural products are in most cases associated with the enhancement or alteration of 
biological potency.  Furthermore, they act as solubility modulators and aid in 
penetration through membranes (Weymouth-Wilson, 1997). Sugar moieties can also be 
associated with self-resistance against the produced compounds (Cundliffe and 
Demain, 2010).  
2.1. Glycosyltransferases 
Glycosyltransferases (GT) are found in each domain of life. These diverse enzymes are 
important in attaching carbohydrates to biomolecules. GTs use two substrates: the 
donor substrate, which donates the sugar moiety to be attached and the acceptor 
substrate, which is decorated by the carbohydrate moiety attached in the process. The 
reaction happens in a regio- and stereoselective manner (Liang et al., 2015). When the 
reaction is completed a glyosidic linkage is formed between the sugar and the 
backbone. The carbohydrate moiety is activated by a leaving group to facilitate the 
attachment. In the case of Leloir GTs – named after the Nobel laureate Luis Federico 
Leloir – the activation is achieved by a nucleoside diphosphate nucleotide or a 
nucleoside monophosphate, whereas with non-Leloir GTs, lipid phosphates or 
unsubstituted phosphates are utilized (Lairson et al., 2008). 
 
There are multiple classification schemes for dividing GTs into different groups. The 
traditional division is the Leloir and non-Leloir division as mentioned above. Division 
based on the fold is the most common, with further subdivision into clans based on the 
utilized mechanism (I and II: inverting, III and IV: retaining) and finally to families 
based on the sequences (Coutinho et al., 2003; Liu and Mushgenian, 2003). GTs can 
also be divided into processive and non-processive GTs, which denotes whether or not 
the acceptor substrate is released between additional reaction cycles that attach 
subsequent sugars (Price et al., 2002). In total, there are nearly 100 families of GTs. 
The sequence similarity between GTs is generally low, except within a specific GT 
family. The CAZy-database of GTs contains current information on GTs and other 
enzymes involved in carbohydrate metabolism, such as glycoside hydrolases, 
polysaccharide lyases, and carbohydrate esterases (Lombard et al., 2014; 
www.cazy.org). Correspondingly, the 3D structures of GTs that have been solved are 




The accuracy and substrate specificity varies greatly. In many cases, GTs have been 
shown to exhibit flexible substrate specificity, especially regarding the donor sugar but 
also the acceptor aglycone (e.g. Borisova et al., 2006; 2008; Minami and Eguchi, 2007; 
Minami et al., 2005; Trefzer et al., 2002; Yang, M. et al., 2005). Nevertheless, there 
are GTs that are not shown to be promiscuous or that show very limited promiscuity 
under the tested conditions (e.g. Albermann et al., 2003; Freel Meyers et al., 2003; 
Oberthür et al., 2005).  
2.1.1. Glycosyltransferase Folds 
The amino acid sequence similarity between GTs is generally low. However, protein 
crystallography has revealed that there is limited variation in 3D structures, and there 
are only two main folds, denoted as GT-A and GT-B (Bourne and Henrissat, 2001; 
Coutinho et al., 2003). The GT-A fold (Fig. 2A) has been described as a single-domain 
enzyme (Chang et al., 2011b; Thibodeaux et al., 2008), although others have noted that 
it is formed by two closely adjoined domains that resemble β/α/β Rossmann folds 
(Lairson et al., 2008; Ünligil and Rini, 2000). The catalytic site is situated between two 
distinct binding sites for the donor and acceptor molecules and there is a 
conformational change upon binding (Liang et al., 2015). Enzymes containing the GT-
A fold generally rely on a divalent metal ion, such as Mg2+ or Mn2+, and consequently, 
a metal binding motive – DXD or EXD – is found in most sequences. The metal is 
proposed to stabilize the charged phosphate group of the donor substrate (Fig. 6–7; 
Charnock and Davies, 1999; Ünligil and Rini, 2000). However, there are examples of 
GT-A proteins where the metal binding motive is not found (Pak et al., 2011; Qasba et 
al., 2005), and in these cases the stabilization of the transition state is most likely 
achieved in a manner similar to the metal-independent GT-Bs described below. Some 
GT-A enzymes have the globular catalytic domain linked to a transmembrane region 
and a small cytoplasmic domain in the N-terminus (Breton and Imberty, 1999; Morgan 
et al., 2013).  
Proteins of the GT-B family (Fig. 2B) are composed of two domains with Rossmann-
type folds. This fold clearly consists of two distinct domains: the N-terminal acceptor 
(aglycone) binding and the C-terminal donor (NDP-sugar) binding domain. The 
domains are facing each other and are joined together by a flexible linker. The 
formation of the glycosidic bond takes place between these domains (Moncrieffe et al., 
2012; Mulichak et al., 2003; Qasba et al., 2005). Structural and biochemical analysis of 
GT-Bs has shown that the binding of the substrate induces the protein loops to change 
their conformation, shifting the relative locations of the Rossmann-type domains. This 
indicates a conformational selection or induced fit; thus the protein has an open and a 
closed conformation (Chang et al., 2011a; Hu et al., 2003; Mulichak et al., 2003; 





















Figure 2. Examples of the different glycosyltransferase folds. A) GT-A fold, the example is 
SpsA, the GT involved in the formation of the spore coat of Bacillus subtilis (PDB: 1H7L, 
Tarbouriech et al., 2001), B) GT-B fold, the example is SnogD, the GT involved in the 
nogalamycin biosynthesis (PDB: 4AMG, Claesson et al., 2012), C) GT-C fold, the example 
is PglB, the GT that attaches oligosaccharyl moieties in Campylobacter lari  (PDB: 3RCE, 
Lizak et al., 2011), D) GT-D fold found in Streptococci parasanguinis in the domain that 
glycosylates Streptococcal adhesins (PDB: 4PFX, Zhang, H. et al., 2014), E) lysozyme-like 
fold, the example is the peptidoglycan glycosyltransferase domain involved in 




catalyze reactions in the absence of a metal-ion (Lairson et al., 2008; Gloster, 2014), 
which is compensated by positively charged amino acids or a helix dipole (Fig. 6–7; 
Breton et al., 2012). The fact that GT-A and GT-B folds both contain Rossmann-type 
domains indicates that they belong to the Leloir GTs.   
In addition to these most prevalent folds, there are rarer folds emerging as more 
structural studies are progressing. The GT-C fold (Fig. 2C) is found in membrane-
bound enzymes and thus contains transmembrane helixes spanning the membrane 
(Igura et al., 2008; Lizak et al., 2011; Maita et al., 2010). Many of the structures are 
limited to the truncated soluble C-terminal domains (Igura et al., 2008; Maita et al., 
2010) due to difficulties in unraveling of 3D structures of membrane proteins, and only 
one structure of an entire protein is available to date (Lizak et al., 2011). The lack of a 
Rossmann-type fold together with the fact that the protein resides on a membrane 
suggest that the sugars transferred by this type of GT are all activated by lipid 
phosphates (Igura et al., 2008; Maita et al., 2010). Similarly to the GT-A fold, the GT-
C fold utilizes a divalent metal, but it appears to have a dual role, not only stabilizing 
the leaving group, but also orienting acidic residues to interact with the acceptor 
molecule (Lizak et al., 2011).  
The GT-D fold (Fig. 2D) is found in pathogenic Streptococci and fusobacteria (Zhang, 
H. et al., 2014). It is related to the bacterial adhesin synthesis, and thus the GTs 
exhibiting this fold may play a role in the pathogenicity of these bacteria and hence be 
considered targets for drugs (Zhou and Wu, 2009). The fold contains three regions, a 
central Rossmann-type fold, flanking the C-terminal region and an N-terminal metal-
binding motive, DXE, which is distinct from the GT-A metal-binding motive and 
cannot be replaced by another metal-binding motive (Zhang, H. et al., 2014).  
The lysozyme-like fold (Fig. 2E) has thus far been found in enzymes related to 
peptidoglycan synthesis (Lovering et al., 2007; Yuan et al., 2007). The fold resembles 
the fold found in λ-lysozyme, but instead of hydrolyzing the carbohydrates of the 
peptidoglycan surface, it attaches them and forms the carbohydrate chains on the 
bacterial cell wall to form peptidoglycan (Lovering et al., 2007; Yuan et al., 2007).   
Based on sequence prediction, there are GTs that do not seem to belong to any of these 
folds, for example the in silico proposed GTS-D superfamily fold (Kikuchi et al., 
2003), but upon experimental data the conclusions may still change. All known GTs 
involved in polyketide biosynthesis - and most GTs in natural product biosynthesis in 
general - are Leloir GTs and possess the GT-B fold. A recently found exception is 
Ram29, which belongs to the GT-C fold. It is a polyprenyl phosphomannose dependent 
GT, which is involved in the biosynthesis of enduracidin, a polypeptide antibiotic, but 




2.1.2. Sugar Linkage 
The sugar moieties can be attached by different linkages to the aglycone moiety. The 
most common mode of attachment is the O-glycosidic bond in which the oxygen is 
derived from the sugar moiety. The rarer linkages are the C-glycosidic, N-glycosidic, 
S-glycosidic, hydroxylamine or orthoester bonds (Thibodeaux et al., 2008). The type 
of bond is expected to affect stability; for example the O–C bond is the most prone to 
spontaneous hydrolysis, and the C–C bond is the most stable. For these reasons, the 
type of linkage is important for the stability of the final compound and also influences 
applicability in medicine (Bililign et al., 2005). For instance, some O-glycosylated 
compounds are prone to deglycosylation in the acidic environment of the stomach, 
which prevents oral administration of the drugs (Hultin, 2005).  
A specific GT typically makes just one kind of bond.  Nevertheless, there are examples 
of natural or engineered GTs exhibiting a bifunctional nature in terms of the linkage. 
These examples are found in plants and yeast making both O- and N-linkages (Loutre 
et al., 2003; Xu et al., 2013), or O/C-glycosylating enzymes found in e.g. bacteria and 
plants (Dürr et al., 2004; Gandia-Herrero et al., 2008) and even trifunctional (O-/S-/N-) 
GT from bacteria (Gantt et al., 2008). This feature makes it more difficult to 
understand what causes a specific linkage to be formed. Nevertheless, studies have 
given insight into the preference of linkage formation. The Bechthold group altered a 
strictly C–O bond forming GT to a strictly C–C bond forming GT (Härle et al., 2011). 
The O–C forming GT, UrdGT2, from the urdamycin pathway was altered by rational 
design to mimic the C–C forming GT, LanGT2, from the landomycin pathway (Härle 
et al., 2011). Further structural studies led to a model where the cause of the different 
linkage forming capacity lies in the conformation of the substrate in relation to the 
protein and, more specifically, to the nucleophile needed for catalysis (Tam et al., 
2015).  
2.1.3. Substrates for the Glycosyltransferase  
There are several different aglyca that act as acceptor substrates in GT reactions. A 
comprehensive presentation of aglyca including a wide range of different polyketides 
and other aglyca such as nucleosides and peptides as well as sugars is demonstrated in 
the detailed review by Elshahawi et al., 2015.  
2.1.3.1. The Acceptor Substrate 
Polyketide aglyca are built by PKS from simple compounds bound to coenzyme A, 
which are called the starter and the extender units (Fischbach and Walsh, 2006). In the 
case of type II PKS, the starter and extender units can be for example acetyl-CoA and 




condensation reactions, a carbon chain is built by the minimal PKS, which consist of 
two ketosynthase units and an acyl carrier protein. Further modifications to the carbon 
chain, such as cyclizations, are made depending on the final structure (Hertweck et al., 
2007; Khosla et al., 1999). As an example of possible aglycone structures, only a few 
possible aglyca are shown in Figure 3 (Elshahawi et al., 2015).  
2.1.3.2. The Donor Substrate: the Activation of the Sugar 
The second substrate for the GT is the donor substrate, which is the attached sugar. The 
precursor for it is a monosaccharide-1-phosphate derived from primary metabolism. 
One well-studied route is the Leloir pathway, which converts β-D-galactose via 
multiple steps to D-glucose-1-phosphate (Frey, 1996; Holden et al., 2003). Glycogen, 
fructose or glucose can also be utilized as the precursor for the biosynthesis of the 
attached sugar. In the example shown in Figure 3, the biosynthesis starts from glucose, 
which is phosphorylated by a hexose kinase to glucose-6-phosphate and converted to 
glucose-1-phosphate by a phosphohexomutase (Fig. 3B–D; Lu and Kleckner, 1994).  
After the phosphate group has been transferred to the anomeric position, the sugar has 
to be activated with a leaving group in order for it to be a suitable substrate for a GT 
(Lairson et al., 2008). In the case of Leloir GTs, the activation is achieved by a 
nucleoside diphosphate nucleotide or a nucleoside monophosphate, whereas with non-
Leloir GTs, lipid phosphates or unsubstituted phosphates are utilized (Lairson et al., 
2008). Typically, GTs involved in the glycosylation of polyketides use activated 
diphosphate nucleotides as the leaving group of the donor substrate. Consequently, the 
nucleotide activated sugars are the focus of this thesis. The typical precursor, glucose-
6-phosphate, is the sugar moiety for dTDP-, CDP- and UDP-activated sugars (Fig. 3E; 
Singh et al., 2012). In natural product biosynthesis, the most prevalent nucleotide used 
by bacterial GTs is dTDP (Thibodeaux et al., 2008). All bacterial GTs with available 
crystal structures that are involved in polyketide biosynthesis use either dTDP or UDP 
as the leaving group. Furthermore, the structural data on GTs suggest that, in the case 
of dTDP-utilizing enzymes, the preference of dTDP over UDP is rather stringent, 
because the nucleotide-binding pocket has a steric obstruction of the 2´-OH of the 
ribose, which hinders the binding of UDP (Isiorho et al., 2014; Wang et al., 2013).  
The NDP-hexose nucleotidyltransferase, which can also be called NDP-hexose 
synthetase or NDP-hexose pyrophosphorylase, is responsible for the attachment of an 
NTP to the sugar moiety (Fig. 3E). The reaction is proposed to happen in a Bi-Bi 
ordered manner, where first the NTP molecule binds to the enzyme and subsequently a 
phosphate or a pyrophosphate is removed. Finally, in a typical scenario, an α-sugar is 
linked to the corresponding NDP or NMP (Barton et al., 2001; Blankenfeldt et al., 
2000; Zuccotti et al., 2001). Similarly to the GTs, the nucleotidyltransferase fold 




















Figure 3. A schematic overview of the sugar modifications and attachment to the aglycone. 
A) The aglycone is synthesized. B) The sugar is derived from primary metabolism, in this 
example D-glucose, C) the sugar is phosphorylated by a hexose kinase, resulting in 
glucose-6-phosphate D) and the phosphate group position is changed by a 
phosphohexomutase, resulting in glucose-1-phosphate E) and activated by an 
nucleotidyltransferase, F) altered by a hexose-4,6-dehydratase G) and modified further. 
H) The activated sugar is attached to the aglycone I) and finally possible post-
glycosylation events may take place. In the picture, as an example, is the deoxy sugar of 
nogalamycin; L-nogalose, which is attached to the aglycone by SnogE, and the methylation 
reactions are achieved by the actions of SnogY, SnogL and SnogM, which are proposed to 
happen after the attachment to the aglycone (Singh et al., 2012, Thibodeaux et al., 2008; 




As in the GT-A fold of GTs, a divalent metal stabilizes the leaving group. The 
activation of sugars by the attachment of a nucleotide is also part of primary 
metabolism, where it is utilized, for example, in cell wall and glycogen synthesis 
(Holden et al., 2003; Zuccotti et al., 2001). The congruence of the primary and 
secondary metabolism is highlighted by the fact that there are cases where the 
nucleotidyltransferases associated with secondary metabolism may not be included in 
the gene clusters of the corresponding polyketides but are in fact the same genes that 
are expressed for primary metabolism elsewhere in the genome (Thibodeaux et al., 
2008). However, this may also be pathway-dependent, since there is also evidence for a 
nucleotidyltransferase that is specific for secondary metabolism (Kudo et al., 2005). 
2.1.3.3. The Donor Substrate: the Modification of the Sugar 
After the activation of the sugar, the next shared step in the biosynthesis of unusual 
sugars is the dehydration of the sugar (Fig. 3F). The SDR fold containing NDP-hexose-
4, 6-dehydratase creates an NDP-4-keto-6-deoxy sugar in a stepwise manner. The 
protein is NAD(P)+-dependent and catalyzes C4´ oxidation, C5´/C6´ dehydration and 
C5´/C6´ ene reduction of the sugar (Allard et al., 2002; Singh et al., 2012). This 
reaction is considered irreversible and is the final common step for the sugar moieties 
involved in the biosynthesis of sugars attached to polyketides (He and Liu, 2002; 
Lombó et al., 2009). As in the case of nucleotidyltransferases, the gene for the NDP-
hexose-4, 6-dehydratase has also been speculated in some cases to reside outside the 
corresponding gene cluster, for example in the case of the sugar moiety L-daunosamine 
found in daunorubicin and doxorubin (Trefzer et al., 1999).  
Most of the modifications to carbohydrates happen to the nucleotide bound sugars 
before the attachment to the aglycone (Field and Naismith, 2003; Thibodeaux et al., 
2008). These include epimerizations, isomerizations, hydroxylations, transaminations, 
deoxygenations, oxidations, amino oxidations, pyranose/furanose interconversions, 
dehydrations, reductions, and group transfers such as methylations (Singh et al., 2012).  
The further modifications made to the sugars after the attachment of the NDP – some 
of which are briefly discussed in the following sections – are not universal to all 
unusual sugars (Fig. 4; Salas and Méndez, 2007). More information on the sugar-
modifying enzymes can be found in the detailed reviews (e.g. Field and Naismith, 
2003; He et al., 2000; He and Liu, 2002; Singh et al., 2012; Thibodeaux et al., 2008).  
One important and prevalent modification made to the sugars is dehydration at 
different positions of the sugar. Dehydrations are needed to achieve a reactive 
ketosugar, which is required for other modifications, such as the addition of an amino 
group. The dehydratases belong to two different classes: the SDR-fold dehydratases 



















Figure 4. Examples of possible modifications made to the common intermediate (from Fig. 
3E) of the sugar moiety biosynthesis. Modifications are made to different positions (C2–
C5) marked with purple spheres and divided into different corners of the figure. The 
figure was inspired by Salas and Méndez, 2007. 
aminotransferases (Smith et al., 2008). Amino group containing sugars are generated 
by aminotransferases, which attach an amino group from an amino donor (L-Glu, L-Gln 
or L-Asp) to an NDP-ketosugar by utilizing PLP as the cofactor. The stereochemistry 
of the attached amino group may differ depending on the pathway. These differences 
are suggested to result from different orientations of the sugar in the active site of the 




The sugar epimerases or isomerases invert the stereochemistry of an asymmetric 
carbon of the sugar. There are several types of enzymes catalyzing epimerization 
reactions, and they use different strategies (Allard et al., 2001). Cupin-type epimerases 
remove a proton from one side of the sugar, creating an instable enolate, which is 
subsequently protonated from the other side of the sugar (Dong et al., 2007; Dunwell et 
al., 2001; Giraud et al., 2000). The enzymes of the second epimerase family have an 
SDR-fold and require NAD(P)+ as cofactors. In the proposed reaction mechanism, a 
hydride is removed from one side of the sugar and introduced to the other side, thus 
changing its stereochemistry (Frey and Hegeman, 2013; Lau and Tanner, 2008; Major 
et al., 2005). A different approach is used by the GT-B type epimerase, which 
eliminates the attached nucleotide and reintroduces it to the molecule from the opposite 
side, resulting in an altered stereochemistry (Campbell et al., 2000). The newest 
example of a sugar epimerase is the α-KG-dependent epimerase, which we found to be 
involved in nogalamycin biosynthesis, where it creates the epimer of the amino sugar 
at position C4´´ [Fig. 11: 10, 12, 16]. The mechanism differs from the other known 
sugar epimerases, as it is proposed to create a radical intermediate. Moreover, the 
reaction takes place only after the attachment of the carbohydrate (Siitonen et al., 
2016). A similar enzyme was first discovered in carbapenem biosynthesis, but there the 
epimerization reaction does not take place on a sugar molecule (Chang et al., 2014). 
Sugar ketoreductases reduce the reactive 3- or 4-ketosugar intermediates to the 
corresponding secondary alcohols with either stereochemistry (Thibodeaux et al., 
2008). The reduction results in deactivation of the carbohydrate and takes place after 
other chemical transformations, which have required unstable intermediates with 
carbonyl functional groups. Probably because of this, the ketoreductases are 
widespread among the biosynthetic pathways of sugars. The enzymes are found to 
have two folds: the SDR (Blankenfeldt et al., 2002) and the glucose-fructose 
oxidoreductase fold (GFOR) (Kubiak and Holden, 2011). Both of these protein 
families require NAD(P)H for activity and, in addition, the SDR enzymes are Mg2+-
dependent. The reduction is achieved by a hydride transfer from NAD(P)H to the 
carbonyl of the NDP-bound sugar (Blankenfeldt et al., 2002; Kubiak and Holden, 
2011).  
Methylations are generally achieved through the addition of methyl groups to the 
sugars through O-, N- or C-bonds. Typically, O-methylations are thought to occur only 
after the attachment of the sugar moieties, whereas N- and C-methylations happen 
before the glycosylation event (Thibodeaux et al., 2008). Methylases require SAM, 
which supplies the methyl group to be transferred. Thus these enzymes contain a 
binding site for SAM. Furthermore, these enzymes display low sequence similarity to 
each other but share a highly conserved fold. Most sugar methyltransferases require a 




bifunctional ketoreductase/methyltransferase, MtmC, from the mithramycin pathway, 
which catalyzes either reaction by using different cofactors (Chen et al., 2015; Wang et 
al., 2012). 
In addition to modifications made to the NDP-bound sugar , examples of post-
glycosylation events are known to exist, but they are much less diverse and mostly 
include group transfers, such as methylation e.g. in steffimycin (Olano et al., 2008) and 
acetylation for example in chromomycin A3 (Menéndez et al., 2004) reactions. In 
Figure 3, L-nogalose from the pathway of nogalamycin serves as an example for 
modifications made to the sugar prior to and following the attachment. Furthermore, 
Figure 3 shows the attachment of L-nogalose to the aglycone, nogalamycinone (Fig. 
3G–I; Siitonen et al., 2012b; Torkkell et al., 2001).  
2.1.4. Mode of Action of the Glycosyltransferases 
As previously mentioned (2.1.), GTs use two substrates, the acceptor and the donor, 
which are attached to each other, while the leaving group, a nucleotide in the Leloir 
type GTs, detaches from the donor substrate. The reaction usually happens in an 
ordered Bi-Bi fashion (Liang et al., 2015). There are examples of GTs where the donor 
substrate binds first (Qasba et al., 2005) as well as of GTs where the acceptor substrate 
binds first (Quirós et al., 2000). To make the matter more complicated, GtfA, the GT 
from the vancomycin biosynthesis, appears to enable the binding of both substrates 
independently without a strict Bi-Bi fashion (Mulichak et al., 2003).  
GTs are found to be either inverting or retaining, which corresponds to the 
stereochemistry of the anomeric carbon of the attached sugar (Fig. 5A–B). Thus if the 
sugar is attached to the nucleotide in an α-configuration, after the attachment by a 
retaining GT the sugar is also an α-anomer, whereas the action of inverting GT results 
in an β-anomer (Breton et al., 2012; Lairson et al., 2008; Sinnot, 1990). Both inverting 
and retaining GTs are found in the two main fold types, GT-A and GT-B, which are 
further divided into clans based on their mechanism (Coutinho et al., 2003). Because 
the fold does not give insight into what kind of a mechanism the GT is using, it has 
proven to be difficult to predict the mechanism based on sequence information alone, 








The mechanism of inverting GTs is proposed to follow a single displacement (SN2) 
mechanism with an oxocarbenium-ion transition state. The proposal is supported by 
structural data (Breton et al., 2012) and quantum mechanics/molecular mechanics 
methods (Tvaroška, 2015). Overall, it is thought to follow a similar mechanism to 
inverting glycoside hydrolases (Lairson et al., 2008). In this mechanism (Fig. 6), the 
acceptor substrate makes a nucleophilic attack on the anomeric carbon of the donor 
substrate, which is aided by the abstraction of a proton from the accepting hydroxyl 
group by a general base, which has been shown to be Asp (Mulichak et al., 2004), Glu 
(Sun et al., 2007), or His (Isiorha et al., 2014). The departure of the leaving group is 
facilitated by different means dependent on the fold. The GT-A fold contains a metal 
binding site, thus a divalent metal assists the phosphate group departure, acting as a 
Lewis acid. In the GT-B fold, there is no metal binding site, thus the departure has to 
be facilitated by other means – by a helix dipole, a side chain hydroxyl, or an imidazole 








Figure 6. Mechanism of the inverting GT according to current knowledge (Lairson et al., 
2008). 
There is evidence for two mechanisms used by retaining GTs: the double-displacement 
mechanism (SN2, Fig. 7A) or a special case of the SN1 mechanism, the internal return 
mechanism (SNi, Fig. 7B). The first proposed mechanism was the double-displacement 
mechanism, which is analogous to the mechanism utilized by retaining glycosidases 
(Lairson et al., 2008). It consists of a covalently bound glycosyl-enzyme intermediate 
(Lairson et al., 2004) and requires a catalytic nucleophile for the reaction. As in the 
inverting clan, the divalent metal is proposed to assist in the departure of the leaving 
group, acting as a Lewis acid. However, there is limited experimental evidence for this 
mechanism at present. Emerging structural data on these clans of GTs have revealed 
that there are cases in which the structures lack elements needed for the proposed 




of the alternative SNi mechanism also. Instead of covalent intermediates, the SNi 
mechanism involves ion pair intermediates, which make it possible to return to the 
starting conditions without the loss of the compounds by possible hydrolysis. The 
nucleophilic hydroxyl group of the acceptor attacks the donor, which is followed by the 
departure of the leaving group to the same side of the attack (Breton et al., 2012).  
 
Figure 7. Two possible mechanisms for the retaining GTs according to current knowledge 
A) double-displacement mechanism, with the covalently bound intermediate (A-int in 
panel C) B) internal return mechanism with the ionic intermediates (B-int in panel C)  
(Breton et al., 2012; Chang et al., 2011b; Lairson et al., 2008). C) Schematic presentation 
of the potential energy barriers for the different intermediates adapted from (Lairson et 
al., 2008) GT: glycosyltransferase, GH: glycosyl hydrolase or glycosidase, A-int: 
intermediate from mechanism A and B-int: intermediate from mechanism B.  
The intermediate of the alternative SNi mechanism has a higher energy level than the 
intermediate of the double displacement mechanism (Fig. 7C), but at the same time, the 
alternative SNi mechanism makes the hydrolysis of the intermediate less likely. 
Furthermore, in the case of GTs, the substrate carries a high energy leaving group, and 
thus the energy barrier in both cases (SNi and the double displacement mechanism) is 
lower than that of the corresponding retaining glycosidases, which do not have a high 
energy substituent. There is currently more supporting evidence for the SNi mechanism 
(Ardèvol et al., 2016; Gómez et al., 2012; Lairson et al., 2008). However, there may be 




The mechanism of the O–C bond formation has been well studied, as it is the most 
prevalent linkage. However, there have also been investigations into the mechanism 
regarding the formation of the C–C bond forming GTs (Bililign et al., 2004; 2005; 
Dürr et al., 2004; Gutmann and Nidetzky, 2012; Härle et al., 2011; Tam et al., 2015). 
Two mechanisms have been proposed for that the C–C bond formation: the ortho/para 
directed O- to C-glycosyl rearrangement (Fig. 8A) and a direct Friedel–Craft alkylation 
(Fig. 8B). In the first mechanism mentioned, the phenolic hydroxyl group is O-
glycosylated, which is followed by O–C rearrangement. Usually the ortho-C-









Figure 8. Possible mechanisms for the C–C bond forming GTs A) O- to C-glycosyl 
rearrangement B) a direct Friedel–Craft aromatic substitution (Bililign et al., 2004; 
Thibodeaux et al., 2007; 2008).  
amounts. In the second mechanism mentioned, the phenolate anion of the acceptor 
substrate attacks the anomeric carbon of the NDP-sugar, thus directly forming a C-
glycoside (Bililign et al., 2004; Dürr et al., 2004; Thibodeaux et al., 2008). The studies 
on  UrdGT2 and LanGT2 gave evidence for a direct Friedel–Craft alkylation, as 
mutants with an altered function (O–C  bond forming to C–C bond forming enzyme) 
do not produce C–O linked compounds even in small amounts (Härle et al., 2011). 
2.1.5. Auxiliary Proteins of Glycosyltransferases 
Some GTs have been shown to require an auxiliary protein for activity, e.g. from the 
pathway of tylosin, indolocarbazole and daunorubicin (Melançon III et al., 2004; Otten 
et al., 1995; Salas et al., 2005). DesVIII, a protein expressed by S. venezuelae, which is 




auxiliary protein required for GT activity (Borisova et al., 2004). Later, more putative 
auxiliary proteins were found based on sequence homology and, in most cases, the 
genes coding for the auxiliary proteins were found immediately upstream of the gene 
encoding the corresponding GT (Melançon III et al., 2004; Otten et al., 1995). 
Replacement of the auxiliary protein by a homologous enzyme from another species in 
vitro (Yuan et al., 2005) and in vivo (Hong et al., 2007; Wu, H. et al., 2015) showed 
that many of the auxiliary proteins can work with an unnatural partner. Furthermore the 
study showed that the specificity of the partner is in the interaction between the 
proteins, the GT and the auxiliary protein, not between the auxiliary protein and the 
substrate or product (Borisova and Liu, 2010). On the other hand, the study on the 
spiramycin gene cluster leaves room for speculation, as there are two auxiliary proteins 
each associated with a different GT. While one of the auxiliary proteins can activate 
both GTs, the other cannot (Nguyen et al., 2010). Although the auxiliary proteins are 
typically associated with the transfer of amino sugars, there is in vitro evidence that the 
transferred moiety may be a sugar without an amino group (Borisova et al., 2006), but 
such examples from in vivo studies have not emerged.  
Initial in vitro findings suggested that the auxiliary protein is needed for the activation 
of the GT rather than for the transfer reaction itself; this has been shown for EryCIII 
(Yuan et al., 2005) and for DesVIII (Borisova et al., 2006). Later, it was proposed that 
the auxiliary protein together with the GT form a tight complex, which is only formed 
by the co-expression of the two proteins in the same host. This complex was shown to 
significantly increase activity compared to the action of an “activated GT”, where a 
separately purified auxiliary protein and GT are mixed together (Borisova and Liu, 
2010). Biochemical characterization of AknT and AknS, the auxiliary protein and GT 
from the aclacinomycin A pathway, respectively, demonstrated that the two proteins 
form a stable complex (Leimkuhler et al., 2007; Lu et al., 2005). The interaction 
between the partners was confirmed by crystallographic studies with the first 3D 
structure of an auxiliary protein (EryCII) together with the GT (EryCIII) from the 
biosynthetic pathway of erythromycin D (Moncrieffe et al., 2012). The structural data 
showed a tight complex of a dimer of heterodimers and indicated a stabilizing effect of 
the auxiliary protein to the GT. Moreover, the authors proposed that it would 
specifically change the acceptor site of the GT, thus being an allosteric activator. The 
fold of EryCII resembles the fold of cytochrome P450 proteins. The auxiliary proteins 
lack the conserved Cys residue, which is required for coordinating to the heme, but 
contain an additional N-terminal helix, which provides an interface for the interaction 
between the GT and the auxiliary protein (Moncrieffe et al., 2012). When the SpnG 
GT, which is involved in the biosynthesis of spinosyn A was investigated a motif for 
the interaction between the GT and an auxiliary protein was proposed (H-X-R-X5-D-




auxiliary protein has not been identified, so it is possible that there is a distinct class of 
auxiliary proteins not yet recognized (Isiorho et al., 2014). 
2.2. Glycodiversification 
Glycodiversification is derivatization of natural product sugar moieties through 
exploitation of the sugar biosynthetic machinery (Thibodeaux et al., 2008). Sugar 
moieties play a significant role in the biological activity of polyketides, and thus there 
is a huge interest in altering the glycosylation patterns, as it might lead to more potent 
compounds. Nonglycosylated compounds can be glycoconjugated to improve them 
(Gantt et al., 2008), or the intrinsically attached sugar moieties can be altered to change 
their pharmacological or pharmacokinetic properties (Ge et al., 1999). The added or 
altered sugar moieties can change for instance the solubility, toxicity or KD of binding 
to their target (Křen and Řezanka, 2008). In a study on warfarin, it was shown that 
even the target of the compound was altered because the compound was converted 
from an anticoagulant to a cytotoxic agent upon glycosylation (Peltier-Pain et al., 
2011). Altering the sugar moieties in polyketides may also help overcome bacterial 
resistance (Nguyen et al., 2010). In many cases, drug resistance arises from mutations 
to the drug target. Drug resistance can be overcome by changing the drug so that it will 
recognize the mutated target (Liu and Douthwaite, 2002; Nguyen et al., 2010). Another 
way for bacteria to become drug-resistant is by developing the ability to discharge the 
drugs out of the cells. By altering the drugs, for example by altering the glycosylation 
patterns, this efflux of the drug may be inhibited (Fang et al., 2006). In addition to 
altering the individual sugars, there is also interest in altering the length of the sugar 
chain (Cipollone et al., 2002; Pratesi et al., 1998; Zhang, G. et al., 2005) to enhance 
cytotoxicity and, on the other hand, to lessen side effects, as for example in the case of 
aclacinomycin A (Oki et al., 1975). It contains three sugars and it has been noted to be 
less cardiotoxic than daunomycin, which contains only one sugar (Weymouth-Wilson, 
1997).  
Furthermore, as previously mentioned, there are cases where the carbohydrate units are 
involved in self-resistance (Bolam et al., 2007; Cundliffe and Demain, 2010; Kwan et 
al., 2010; Vilches et al., 1992). This phenomenon can be utilized in the drug industry 
by creating prodrugs with more sugar moieties than the final drug to improve solubility 
and to lessen toxicity at the time of consumption (Bagshawe, 1987; Křen and Řezanka, 
2008; Senter et al., 1988). When the drug reaches its intended environment, the surplus 
sugars are cleaved off either by increased endogenous activity of β-glucuronidase in 
the inflamed tissue in prodrug monotherapy or by the use of an antibody-directed 
prodrug therapy, where α/β-glycosidases are directed to the site of the tumor while the 




sugars on the tumor site, and the prodrug becomes an active drug (Bagshawe, 1987; 
Křen and Řezanka, 2008; Senter et al., 1988). 
In order to change the glycosylation patterns of a given molecule, one approach is to 
utilize the inherent flexibility of the enzymes involved in the biosynthesis. 
Nevertheless, in many cases there is only very limited or no inherent promiscuity, and 
thus one important approach is to alter the proteins related to the synthesis of 
glycosylated products. Examples of alterations to the enzymes involved in sugar 
biosynthesis will be discussed in 2.2.1. To create novel compounds with altered 
glycosylation patterns, one can approach the matter in vitro or in vivo or with a 
combination of both approaches. These will be discussed in 2.2.2. Different forms of 
glycodiversification have been reviewed in several articles (e.g. Griffith et al., 2005; 
Luzhetskyy and Bechthold, 2008; Luzhetskyy et al., 2008; Méndez et al., 2008; Salas 
and Méndez, 2007; Thibodeaux et al., 2008). 
2.2.1. Engineering Enzymes Involved in the Sugar Biosynthesis 
2.2.1.1. Anomeric Position Phosphorylating Enzymes 
The phosphorylation of the sugar can be considered the first step in the sugar 
biosynthesis (Fig. 3C) for glycosylation of polyketides. As discussed in 2.1.3, the 
phosphorylating enzymes typically use naturally occurring sugars for example 
glycogen phophorylases creating D-glucose-1-phosphate, fucokinase forming β-l-
fucose-1-phosphate, and galactokinase generating α-D-galactose-1-phosphate (Holden 
et al., 2003; Johnson and Braford, 1990; Park et al., 1998). The natural substrates for 
these enzymes are thus sugars derived from the primary metabolism. If the natural 
substrate has been altered prior to phosphorylation, for example by chemical synthesis, 
the original anomeric kinase may not recognize the sugar as a substrate, as the 
anomeric kinases usually act on the early stage of sugar biosynthesis. In approaches 
where the sugar has been altered prior to phosphorylation it would be beneficial to 
have an anomeric kinase, which can tolerate variation in mass or additional groups in 
the sugar moiety. In an example, the E.coli enzyme GalK, which naturally uses D-
galactose and ATP as its substrates, was randomly mutated to be more permissive. 
Initially, the authors generated a variant that was able to accept differences in most 
positions of the sugar, but the C4 position of the sugar had to resemble the galactose 
structure (Hoffmeister et al., 2003b; Yang et al., 2003). However, a permissive variant 
was finally found in further rounds of mutagenesis (Hoffmeister and Thorson, 2004; 
Yang, J. et al., 2005). In these studies mentioned, the authors used a combination of 






The attachment of the nucleotide by the sugar-1-phosphate nucleotidyltransferase (Fig. 
3E) follows phosphorylation of the sugar. The alteration of the nucleotidyltransferase 
substrate specificity can lead to an expanded pool of available NDP-sugars for 
attachment by the GT. Similarly to the GTs, the nucleotidyltransferases are known to 
be inherently promiscuous (Jiang et al., 2000; 2001; Zhang, Z. et al., 2005). One 
extensively studied target for alterations is RmlA (also known as Ep), a 
thymidylyltransferase from Salmonella enterica typhimurium LT2 (Lindquist et al., 
1993; Barton et al., 2001). Another target has been the thymidylyltransferase Cps2L 
from Streptococcus pneumoniae (Jakeman et al., 2008). The wt RmlA is already 
capable of accepting all naturally occurring NTPs, but at varying level of catalytic 
efficiency. Mutant and wt RmlA have been used to make NDP-sugar libraries (Jiang et 
al., 2000; 2001; 2003). There have been efforts in expanding the promiscuity of the 
enzyme by single point mutations targeting i) the sugar and ii) the nucleotide moiety 
acceptance (Barton et al., 2002; Moretti and Thorson, 2007) and whole gene error 
prone PCR and site saturation mutagenesis to expand the activity towards non-native 
substrates (Moretti et al., 2011). Finally, the altered activities can be assessed by an 
MS-based method (Zea and Pohl, 2004).  
According to Moretti and Thorson (2007), the ultimate goal is to produce a single 
universal nucleotidyltransferase, which can accept all nucleotides as well as sugars. On 
the other hand, the nucleotide is important for binding to the GT, as mentioned in 2.1.3. 
Thus, if the nucleotidyltransferase attaches all nucleotides, the risk is that the 
downstream working GT only accepts one kind of nucleotide, so the entire pool of the 
newly created sugar nucleotides would not be accepted by the GT. Hence, one goal 
might also be to achieve a promiscuous nucleotidyltransferase with regard to the sugar 
moiety but stringent towards the attached nucleotide in order to assist the downstream 
working GT. 
2.2.1.3. Glycosyltransferases 
One major target for achieving altered glycosylation patterns is the GT. GTs exhibit 
inherent promiscuity in many cases. It is more typical that the GTs are flexible towards 
the sugar donor, but there are studies where the GT has displayed promiscuity towards 
both the donor sugar and the acceptor aglycone. These include the macrolide GTs 
DesVII, discussed earlier in 2.1. (Borisova et al., 2006; 2008), OleD, a GT from the 
oleandomycin pathway (Yang, M. et al., 2005), and VinC, a GT from the biosynthesis 
of vicenistatin (Minami and Eguchi, 2007; Minami et al., 2005). There has been 
speculation that the promiscuity towards aglycone comes from the fact that the protein 
only recognizes certain factors, such as planarity, hydrophobicity and that the 




A more thorough study concerning important factors for the acceptance of aglycone 
was done by molecular mechanics calculations and a crystal structure (Minami et al., 
2005). The conclusions were similar; the size of the compound, the spatial arrangement 
of polar groups and the glycosyl accepting position, either a hydroxyl group or an 
amine, were important for substrate recognition and utilization (Minami et al., 2005). 
The inherent promiscuity still seems to be limited to certain structural features (Park et 
al., 2009). 
As discussed in 2.1.2., GTs that attach the sugars by more than one kind of linkage can 
be called multifunctional. GTs that link together more than one kind of sugar but with 
the same kind of linkage are also called multifunctional. As an example, the MtmGIV 
from the mithramycin pathway is able to recognize two distinct donor and acceptor 
substrates (Wang et al., 2012). GTs can also act in an iterative way, attaching identical 
sugars into a single compound. These enzymes may also be called multifunctional, as 
the acceptor varies (Lu et al., 2004; Luzhetskyy et al., 2005; Zhang et al., 2006a). 
However, given the known promiscuity of GTs in many cases, most GTs can act in a 
multifunctional way, even if the biological function is limited to the attachment of only 
one sugar to one aglycone. 
In recent years, there has been an enormous increase in available genomic data, which 
has also affected the available sequences of GTs and enzymes involved in sugar 
biosynthesis, but structural investigations are lagging behind. The structural data are 
important for example for mutational studies, which have followed the identifications 
and characterizations of GTs. OleD, a GT from the oleandomycin pathway, has been 
found to be intrinsically promiscuous (Yang, M. et al., 2005) and has been used as a 
template for improved GTs in many studies (Williams et al., 2007; 2008; 2011). There 
are multiple examples of domain swapping to create chimeric GTs with altered 
specificities (e.g. Brazier-Hicks et al., 2007; Cartwright et al., 2008;  Hoffmeister et 
al., 2001; 2002; Krauth et al., 2009; Park et al., 2009; Truman et al., 2009). Domain 
swapping can lead to different or lax specificity, and it can even lead to an enhanced 
catalytic performance (Truman et al., 2009). One goal can also be to make the GT less 
promiscuous in order to achieve a more efficient GT towards a desired sugar (Ramos et 
al., 2009). Other interesting targets for modifications are to alter the chain length of the 
attached sugars (Krauth et al., 2009) or to change the bond forming capability of the 
GT (Gantt et al., 2008; Härle et al., 2011). 
In order to recognize altered GT activities, robust GT assays are required. One 
challenge is often the lack of an authentic donor. One way to overcome this limitation 
is to investigate the GT activity in a reversed reaction and by monitoring the 
accumulation of the aglycone; instead of attaching the sugar, it is detached from the 




for high throughput screening methods (Wagner and Pesnot, 2010). Examples of 
different assays include an assay relying on pH change, which utilizes the fact that a 
proton is released during the formation of the glycosidic bond (Deng and Chen, 2004; 
Park et al., 2009), and another assay relies on the detection of the released inorganic 
phosphate (Wu et al., 2011). There are also fluorescent-based methods, e.g. a 
fluorescent coupled acceptor is used in a FACS-based method (Aharoni et al., 2006; 
Yang et al., 2010), or assays to detect free nucleotides in fluorescent coupled reactions 
(Kumagai et al., 2014; Lee and Thorson, 2011). 
2.2.2. Approaches in Glycodiversification  
2.2.2.1. In vitro Approaches in Glycodiversification 
There are few examples of in vitro reconstruction of glycosylation or sugar pathways 
(Borisova et al., 2006; 2008; Chen et al., 2000; Takahashi et al., 2006) (simplified 
example Fig. 9A). There are multiple challenges in the approach, such as the amount of 
different cosubstrates needed for the sugar modification steps, the need for unknown 
auxiliary proteins (Kim et al., 2014) as well as the production and purification of the 
individual proteins. Also problematic are the scalability of the reactions, generalization 
of the process, and low yields (Yang et al., 2004).   
One way to generate diverse sugar moieties is by utilizing the reversibility of GT 
reactions (Fig. 9B–E), so that the GT detaches the desired sugar from a compound and 
attaches it to a nucleotide (Fig. 9B). This novel sugar nucleotide can then be used as a 
substrate to glycosylate another aglycone (Zhang et al., 2006a–b). Transglycosylation 
can also be used to move a desired sugar from one aglycone to another (Fig. 9C; Zhang 
et al., 2007), or the aglycone can be changed. This is typically achieved by utilizing 
two GTs, the first detaching the sugar from the original aglycone and the second 
attaching the sugar to the novel aglycone (Fig. 9D; Zhang et al., 2006b). The 
reversibility of the GT reaction can also be utilized with unnatural substrates, as in the 
example where the authors synthesized 2-chloro-4-nitrophenyl azido attached to amino 
sugars and a mutated GT (Fig. 9E; Gantt et al., 2013; Williams et al., 2011). Together 
with the unnatural substrates, a permissive GT and free nucleotides, it was possible to 
create new sugar nucleotides, which in turn could be used to glycosylate the intended 
substrate (Zhang, J. et al., 2014).  
Another way to achieve structural diversity of sugars is to use chemical synthesis 
(Andreana et al., 2002; Northrup et al., 2004a–b). In this approach, the sugars are often 
in a free form without nucleotide activation (Fig. 9F), because this has been proven to 
be laborious to achieve by organic synthesis (Hoffmeister et al., 2003b). There are 
different methods to overcome the problem. One is the approach where the synthesis is 





















Figure 9. Examples of in vitro glycosylations. A) Typical reaction cascade: The sugar is 
first phosphorylated and activated by a nucleotide, followed by enzymatic alterations and 
attachment by a GT to an aglycone. B) Utilizing the reversibility of the GT by detaching 
the sugar from the aglycone and attaching it to a nucleotide, thus creating a novel NDP-
sugar. C) Exchange of the attached sugar by a supplied NDP-sugar. D) Exchange of the 
aglycone usually by two GTs. E) Example of a chemically synthesized donor 2-chloro-4-
nitrophenyl azido amino sugars in a reverse reaction with a permissive GT to achieve 
NDP-sugars. F) Using for example chemical synthesis to generate altered sugars G) the 
sugars are phosphorylated and H) activated and attached to an aglycone. J) Possible 
additional modifications after the attachment. Figure inspired by Griffith et al., 2005; 




synthesis and is easier to combine with enzymatic synthesis (Tanaka et al., 2012). A 
usable substrate for attachment could also be achieved by using for example 
chemically synthesized sugars, a promiscuous anomeric kinase (Fig. 9G) and a 
nucleotidyltransferase in vitro (Fig. 9H). This approach was used to create vancomycin 
derivatives (Fu et al., 2003). These NDP-sugars can then be attached to an aglycone by 
a GT (Fig. 9I). One problem in using anomeric kinases in vitro has been the low yields 
due to substrate (ATP) inhibition. The authors overcame the problem by combining an 
ATP regeneration system to the synthesis (Liu et al., 2015). Other cosubstrate 
regeneration systems have been used in in vitro enzymatic synthesis, as well (Koeller 
and Wong, 2000; 2001). Another problem is the need for large amounts of pure 
enzymes. In one example, this was overcome by recycling the GTs by immobilizing 
OleD GT on hybrid magnetic nanoparticles (Choi et al., 2012). If the sugar is 
generated enzymatically, a multienzyme cascade can be difficult to track and measure. 
For that, an NMR-based method was created (Singh et al., 2014). 
Finally, novel sugars can be achieved by altering the sugar moieties only after their 
attachment to the aglycone. One way of doing this is through the addition of functional 
groups to the sugar moieties of the glycosylated products by chemical synthesis (Fig. 
9J; Nicolau et al., 2001). The other alternative is to use sugar modifying enzymes, 
which naturally work after the glycosylation, but in that case the substrate specificity of 
the enzymes may prove problematic, if the novel substrate is considerably different 
from the natural substrate. 
2.2.2.2. In vivo Approaches in Glycodiversification 
One approach to achieve altered glycosylation patterns in vivo is to utilize a 
heterologous host expression system (Fig. 10A). The heterologous host facilitates gene 
inactivation experiments (Fig. 10B) and is in many cases needed for efficient genetic 
modifications. The heterologous host expression system can also help to verify the 
boundaries of the gene cluster and to determine the functions of genes and the 
enzymes. The first examples of cloning and expressing the whole cluster for polyketide 
production in a heterologous host are from the 1980s (Malpartida and Hopwood, 1984; 
Motamedi and Hutchinson, 1987).  
The strains which are lacking in vivo gene inactivation strains may produce compounds 
with altered glycosylation patterns; the biosynthesis may stop at different points, 
leading to compounds with less sugar moieties than in the final product. The sugar 
moieties may be altered by inactivating genes encoding sugar-modifying enzymes, as 
in the example of the pathways of urdamycin A and B. In these studies, multiple genes 
responsible for the alteration of the sugar units were inactivated, and novel 
glycosylated products were obtained (Hoffmeister et al., 2000; 2003a). When 




account to make sure that changes seen in the phenotype of the mutant are indeed due 
to the missing product of the inactivated gene and not for example caused by possible 
problems in expressing the neighboring genes (Thibodeaux et al., 2008). 
In addition to inactivating genes, introducing additional genes to the strains with 
inactivated genes can be used as an in vivo glycodiversification tool (Fig. 10C). The 
first example of an altered sugar moiety in such a way was the alteration of epirubicin; 
it was achieved by replacing the C4-reductase dnrV from the pathway of daunorubicin 
with the corresponding genes avrB or eryBIV from the avermectin or erythromycin 
pathways. The strains produced an epimer of the original compound, a compound not 
found in nature (Madduri et al., 1998). In many cases when altering the compounds by 
in vivo approaches, the yields of the novel compounds can be modest compared to the 
original producers (Borisova et al., 2004). As an example, the inactivation of the C5-
methyltransferase (CloU) from the biosynthesis of clorobiocin led to very low yields of 
a novel compound without the methyl group, which was due to the limited substrate 
specificity of the C4-ketoreductase (CloS), which catalyzes the subsequent reaction on 
the pathway. The problem was solved by introducing another C4-ketoreductase from 
another pathway (OleU from the oleandomycin pathway) to the strain with the 
inactivated gene, thus leading to satisfactory yields of the novel compound (Freitag et 
al., 2006). In addition, the host can alter the glycosylation profile through the action of 
endogenous genes that may interfere with the biosynthesis and lead to further 
diversification of the metabolites produced (Borisova et al., 1999; Hoffmeister et al., 
2000; 2003a; Siitonen et al., 2012b). The problem of this kind of glycodiversification 
is that the pattern may differ between cultivations, as the expression of individual 
genes may differ, and thus reproducibility may be compromised. Furthermore, if the 
GT shows insufficient or no promiscuity, it might lead to a situation where novel 
sugars are created in the cell, but they are not attached to the aglyca. It is also possible 
to replace the original GT by another to create more diversity. In an example, mutant 
strains of Saccharopolyspora erythraea lacking a GT were complemented by GTs 
from another strain, leading to novel compounds in addition to restoring the 
biosynthesis of the original compounds (Doumith et al., 1999). 
Randomly mutating the strain that produces glycosylated products can also lead to 
altered glycosylation patterns (Fig. 10D), as in the case of aclacinomycins produced by 
S. galilaeus (ATCC 31615) (Räty et al., 2000; Ylihonko et al., 1994). The mutations 
were further investigated by complementation with gene products from the original wt 
strain but also from another strain, S. nogalater (Räty et al., 2002). There have been 
similar approaches where sugar biosynthetic genes have been combined in gene 
cassettes to achieve varied combinations of sugars and aglycones. As an example, the 
aglycone of elloramycin was produced from a cosmid in the heterologous host S. 






















Figure 10. Schematic representation of examples of in vivo approaches. A) Heterologous 
host expression of an antibiotic biosynthetic gene cluster. B) A gene inactivated mutant. C) 
Introducing additional genes to a gene inactivated strain. D) Random mutagenesis. E) 
Feeding a strain capable of constructing the aglycone with sugars. F) Feeding a strain 
capable of making diverse sugars with aglyca or intermediates. G) Feeding a strain 
expressing a promiscuous anomeric kinase, a nucleotidyltransferase and a GT with sugars 




products were combined, resulting in novel compounds (Fischer et al., 2002; Lombó et 
al., 2004; Pérez et al., 2005).  
All of the examples mentioned above describe strains that contain all of the 
components required for the production of novel compounds. Another well-established 
approach for the generation of novel compounds is to conduct biotransformation 
experiments, where the strains are fed with either sugars, aglyca (or intermediates) or 
both. It is possible to use a strain that is capable of producing an aglycone and only 
sugars are fed to the strain (Fig. 10E; Yang et al., 2004). Alternatively, only aglyca or 
intermediates are fed to a strain that is producing and making modifications to the 
sugars (Fig. 10F). This approach has been utilized for example with Streptomyces (Han 
et al., 2011) and E.coli as the hosts (Peirú et al., 2008). Doxorubicin analogs were 
generated in the former example and erythromycin D analogs in the latter (Han et al., 
2011; Peirú et al., 2008). The limitation of these kinds of approaches is that only the 
aglycone or the sugar that the strains are capable of producing can be used as the 
scaffolds for the final products. This is overcome by the approach where an E. coli 
strain contains a modified anomeric kinase (Hoffmeister et al., 2003b; Yang, J. et al., 
2005) and a modified nucleotidyltransferase (Barton et al., 2002) alongside a modified 
GT (Fig. 10G; Williams et al., 2011). The sugars and aglyca are both fed to the strain 
and, as a result, the sugars are attached to the aglyca in vivo. The source of the sugars 
and aglyca can vary, for example they can be generated by fermenting in vivo or in 
vitro enzymatically or chemically (Williams et al., 2011). The advantages of these 
methods are that it is possible to use nonphosphorylated sugars without a nucleotide as 
the starting material, and the attached sugar is not determined by the endogenous genes 
of the host. Disadvantages may be the difficulty of getting the aglyca into the cells 
(Williams et al., 2011), but this challenge may be overcome with the use of 
transporters. A universal transporter, which is able to move a broad range of 
compounds out of the cell, could help solve this particular issue (Fernández-Moreno et 
al., 1998; Salas and Méndez, 1998). Another problem may be the toxicity of the 
proteins and the compounds for the heterologous host, which may also cause the strains 
to favor the production of uninteresting, biologically inactive, derivatives (Thorson et 
al., 2004). 
2.2.2.3. Comparison of the in vitro and in vivo Approaches in Glycodiversification 
The benefit of the in vitro approach is that it makes it possible to understand the 
individual steps and the sequence of the steps in more detail compared to studies in 
vivo. Furthermore, by combining enzymes from different pathways, in vitro 





The in vivo approaches typically give better yields and are cheaper but are less 
controllable than the in vitro approaches. Furthermore, the utilized combinations may 
work in vitro, but in vivo the enzymes, substrates, cosubstrates and cofactors may be in 
different locations and the concentrations may be insufficient for the reactions to take 
place (Offen et al., 2006).  
In conclusion, the in vitro approach typically works better as an initial step for better 
understanding of the system, but when one wants to produce these new compounds on 
a larger scale, the in vivo approach or a combination of in vitro and in vivo tackles 
some of the aforementioned problems. Reasons in favor of the in vitro system are 
control over the components and their ratios and easier combination with chemical 
synthesis leading to chemoenzymatic approaches. 
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3. AIMS OF STUDY 
The aim of the study was to gain an understanding of the late stage tailoring steps in 
the biosynthesis of the polyketide antibiotic nogalamycin. The thesis focuses especially 
on the amino sugar moiety of the compound, which is attached in a highly unusual 
fashion by an oxygen–carbon and a carbon–carbon bond.  
More specifically the aims were: 
I  to express the nogalamycin cluster in a heterologous host, elucidate the 
structures of new compounds and identify the genes responsible for the glycosyl 
transfer reactions; 
II  to understand how position C-1 of nogalamycin is hydroxylated prior to 
glycosylation; 
III  to solve the structure of the SnogD GT and conduct structural and functional 
investigations;  
IV  to identify and investigate the enzyme responsible for the C–C bond formation 
and to elucidate how the nogalamine sugar of nogalamycin is formed.  
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4. MATERIALS AND METHODS 
The experimental procedures are described in more depth in the original publications 
(I–IV). A brief overview is presented here. 
4.1. Molecular Biology 
Standard molecular biology methods were used; PCR, molecular cloning using 
digestion of DNA with restriction enzymes and ligation with T4 ligase (Thermo 
Scientific). The E.coli TOP10 cloning strain and the pBAD vector system were used 
for cloning and protein production. E.Z.N.A plasmid mini kit and E.Z.N.A gel 
extraction kit (Omega Bio-Tek) were used for DNA isolation and purification. Phusion 
and DyNAzyme II (New England Biolabs) were used as polymerases in the PCR 
reactions, and the oligonucleotide primers utilized are presented in the corresponding 
articles.  
4.2. Heterologous Expression, Purification and Analysis of Proteins 
E.coli TOP10 cells were grown either in Erlenmeyer flasks or a Fermenter 
(Bioengineering). After the cells reached the density of OD600 0.5–0.8, protein 
production was induced with 0.02 % (w/v) L-arabinose, and the cells were grown for 
16–19 h, typically at room temperature. The cells were collected by centrifugation and, 
depending on the case, were either frozen or used straight away for purification. In 
some applications, the cells were washed prior to purification with PBS.  
The purification was typically performed with TALON resin (Clontech laboratories 
Inc.) and gravity flow with a low imidazole buffer during the beginning and wash steps 
and with a high imidazole concentration during the elution step. Alternatively, a 5 ml 
HisTrap column (GE Healthcare) attached to an ÄKTA system was used. In most 
cases, the buffer was exchanged to an imidazole-free buffer by using a PD10 column 
(GE Healthcare). The purity and size of the proteins were estimated by SDS-PAGE, 
and the concentration was measured by absorbance (NanoDrop2000, Thermo 
Scientific).  
The structures of the proteins were solved by protein crystallography at the laboratory 
of our collaborators at Karolinska Institut. Diffraction data were collected at the 
European Synchrotron Radiation Facility (ESRF), Grenoble, France. Details regarding 
structure refinement are given in the articles. Protein figures were prepared by PyMOL 
(DeLano Scientific LLC). 
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4.3. Enzymatic Assays 
Typical end point measurements were performed in an Eppendorf tube in an end 
volume of 200–1000 µl. The conditions, i.e. the enzyme, substrate and cosubstrate 
concentrations and the buffer conditions, were varied; the details are given in the 
original publications. The reaction mixtures were extracted after the completion of the 
reactions by using chloroform. The chloroform phase was dried under pressurized air 
or in vacuo and dissolved in methanol prior to HPLC analysis. Alternatively, the 
compounds were extracted by solid phase extraction by Discovery DSC-18 columns 
(Supelco, Sigma-Aldrich).  
Reactions demonstrating oxygen dependence were performed in a Thunberg cuvette. 
The enzyme and substrate were kept in separate compartments until oxygen was 
removed by flushing the cuvette multiple times with nitrogen. After the reaction 
mixture was depleted of air, the enzyme was mixed with the other reaction 
components. The reaction was recorded using a spectrophotometer [Multiskan GO 
spectrophotometer (Thermo Scientific)] after which oxygen was reintroduced and 
measured again.    
The consumption of oxygen was measured with the MI-730 Oxygen electrode 
(Microelectrodes). The formation of H2O2 was determined using the HRP/ABTS 
system (Szutowicz et al., 1984). 
The kinetic assays were performed by changing the amount of one component 
(substrate or cosubstrate) and keeping the other components constant. The initial 
velocities were recorded and plotted against the concentration of the varied component. 
Origin was used for fitting the curves (OriginLab Corporation). 
4.4. Heterologous Expression of the Nogalamycin Gene Cluster and 
Gene Inactivation Mutants 
The nogalamycin gene cluster was expressed in a heterologous host S. albus using a 
cosmid pCK505 with an added oriT to allow conjugation sequence as the vector, and 
genes from the nogalamycin gene cluster. The genes from the cluster that did not reside 
in the cosmid were added in an additional vector pIJT486 (Siitonen et al., 2012b). The 
gene inactivated constructs were made on pSnogaori by using the λ Red recombinase 
(Datsenko and Wanner, 2000) and the pFLP2 system (Hoang et al., 1998) using E.coli 
K12 for gene inactivation steps and ET12567/pUZ8002 (Kieser et al., 2000) for 
intergeneric conjugation.  
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4.5. Expression, Isolation and Purification of Compounds 
For analysis or purification of the compounds, the strains were grown in E1soy 
medium (Siitonen et al., 2012b). For small scale analyses, the strains were grown in 30 
ml medium in a 250 ml Erlenmeyer and for large scale in 50 ml (250 ml Erlenmeyer) 
and 100 ml (500 ml Erlenmeyer). 
The compounds were purified in multiple steps. The first step was usually the addition 
of XAD7-resin (Rohm and Haas, 20 gL-1) to the supernatant. The compounds produced 
by the bacteria were absorbed by the hydrophobic resin and then extracted by methanol 
after washing the resin with water. The next step was either open column 
chromatography using normal phase purification and a methanol:chloroform gradient 
or a liquid–liquid extraction either with chloroform and water or with ethyl acetate 
supplemented with 1 % acetic acid and water. The final step before HPLC purification 
was either another liquid–liquid extraction with chloroform or concentration of the 
aqueous phase. The solvents were evaporated using a Rotavapor RII (Büchi). In some 
cases, size-exclusion chromatography in methanol was included [Sephadex LH-20 (GE 
Healthcare)] in the purification scheme.  
The final purification step was done by a preparative HPLC with an UV-detector 
(Merck Hitachi L-6200A), a reverse-phase column (SunFire Prep C18, 5 mm, 10 3 250 
mm, Waters), and a gradient from 10 % acetonitrile to 70 % acetonitrile, both 
containing 18 mM ammonium acetate pH 3.6, or alternatively 15 % acetonitrile 
containing 0.1 % formic acid to pure acetonitrile. 
For the analysis of the in vitro product, multiple large scale in vitro reactions with a 
purified enzyme were performed (e.g. in 40 ml) and subsequently extracted with 
chloroform prior to purification with a combination of size-exclusion [Sephadex LH-20 
(GE Healthcare)] and preparative HPLC. 
4.6. Analysis of the Compounds 
4.6.1. Thin Layer Chromatography  
TLC was used for initial screening or for the fast evaluation of compounds. The mobile 
phase used was typically a mixture of methanol and chloroform (2:8). The TLC plates 
were silica-covered glass or aluminum (Merck). The results were evaluated under 
visible or UV light conditions.  
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4.6.2. High Performance Liquid Chromatography 
Analytical HPLC analyses were performed with a SCL-10Avp HPLC system equipped 
with an SPD-M10Avp diode array detector (Shimadzu) using a SunFire (C18, 3.5 mm, 
2.1 3 150 mm, Waters) or a Kinetex (2.6 µm C18 100 Å, 100 x 4.6 mm, Ea, 
Phenomenex) column. The HPLC analyses were performed as gradient runs. The 
solvents used were either 0.1 % formic acid in a water acetonitrile mixture to pure 
acetonitrile or a mixture containing 18 mM ammonium acetate (pH 3.6) in both 
eluents.  
4.6.3. Mass Spectrometry 
Protein MS was performed at the Centre for Biotechnology (Turku). The samples were 
prepared by running an SDS-PAGE gel upon which the bands were visualized by 
Coomassie staining. The band of interest was isolated and sent for analysis.  
The HPLC electrospray ionization (ESI)-MS analyses of the compounds were 
performed either with a MicrOTOF-Q high resolution MS (Bruker Daltonics) linked to 
an Agilent 1200 Series HPLC system or with a low resolution MS with a HPLC system 
(Agilent 1260 Infinity 6120 Quadropole LC/MS), in most cases with both negative and 
positive modes. For most of the analyzed compounds, the collection of the data was 
more successful in the negative mode, so the values obtained in that mode were used in 
the publications. 
4.6.4. Nuclear Magnetic Resonance 
NMR was performed with either a 400 MHz or 500 MHz instrument (Bruker 
Daltonics). The samples were prepared by drying and dissolving the compounds in 
deuterated solvents, such as methanol-d4, acetonitrile-d3, chloroform-d, acetone-d6, 
DMSO-d6, or a mixture of two solvents. The conducted experiments included 1D 
spectral analyses (13C, 1H, 1D-TOCSY) and 2D measurements (COSY, HMBC, 
HSQC, HSQCDE, NOESY). TopSpin (Bruker Daltonics) was used for spectral 
analysis.  
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5. RESULTS AND DISCUSSION 
5.1. Heterologous Expression of the Nogalamycin Gene Cluster (I) 
The late stages of nogalamycin biosynthesis were the focus of the experimental studies 
of this thesis. Nogalamycin was first discovered in 1965 (Bhuyan and Dietz) and found 
to exhibit activity against Gram-positive bacteria and cancer cell lines, but high 
toxicity prevented its use as medication. Nevertheless, the interesting structural 
features prompted researchers to create a semisynthetic derivative, menogaril, with less 
toxicity (Fig. 11: 2; Wiley, 1979). Furthermore, it inspired us to study the details of the 
biosynthesis of nogalamycin. S. nogalater is the wt producer of nogalamycin, but its 
restriction modification system makes the genetic engineering of the strain difficult 
(Ylihonko, personal communication).  
We utilized the heterologous host expression system to overcome the problems related 
to modifying S. nogalater; the heterologous host made it possible to perform genetic 
modifications on the nogalamycin gene cluster. S. albus (Chater and Wilde, 1980) was 
selected as the heterologous host, as it does not produce any anthracyclines, which 
might interfere with the analyses. We adopted a two-plasmid approach for the 
expression of the whole gene cluster due to the size constraints of the cosmid pKC505 
denoted pSnogaori (Fig. 12). The end product of the strain that harbors the cosmid 
pSnogaori and the plasmid pIJTZOMLTN is nogalamycin (Fig. 11: 1, 13A–C). The 
strain containing only the cosmid pSnogaori, harboring most of the genes of the 
nogalamycin gene cluster, denoted S. albus/pSnogaori is also capable of producing 
anthracyclines. All the examined compounds produced by the strain were found to be 
similar in structure to nogalamycin (Fig. 11: 3–5, 13) with distinctions. Furthermore, 
all the compounds produced by this strain are lacking two methyl groups in the neutral 
deoxy sugar moiety, nogalose. This is logical, since the genes snogM and snogL, which 
are most probably responsible for these steps, are not included in the cosmid pSnogaori 
but reside in the auxiliary plasmid (Fig 12).  
The compound 3´, 4´-demethoxynogalose-1-hydroxynogalamycinone (Fig. 11: 3, 13D) 
is probably an intermediate of the biosynthesis, as it was later also shown to be capable 
of being used as a substrate for sugar attachment (Siitonen unpublished). Nogalamycin 
R (Fig. 11, 13D, 5) closely resembles nogalamycin but lacks an OH-group at the C2´´ 
position and exhibits a different stereochemistry at the C4´´ position of the amino 
sugar, which was determined from the coupling constants obtained from NMR 
analyses. The data revealed that the amino sugar is rhodosamine (J3´ ,́ 4´´: 3.4 Hz), an 
epimer of nogalamine (J3´ ,́ 4´´: 10.5 Hz; Wiley et al., 1977). Based on the structure, we 
hypothesized that the change in stereochemistry was due to the activity of endogenous 
enzymes produced by the heterologous host, S. albus. Nevertheless, later studies  






















Figure 11. The compounds related to the study. 1) Nogalamycin, 2) Menogaril, 3) 3´, 4´-
demethoxynogalose-1-hydroxynogalamycinone, 4) Nogalamycin R, 5) Nogalamycin F,  
6) Nogalamycinone, 7) 3´, 4´-demethoxynogalose-nogalamycinone, 8) Nogalamycin K,  
9) Nogalamycin KO, 10) Nogalamycin RE, 11) Nogalamycin RO, 12) Nogalamycin ROE 
and 13) Nogalamycin RON. 3-13 were analyzed by NMR during the course of this study. 
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confirmed that nogalamycin R may in fact be a true intermediate of the pathway, and 
the stereochemistry is inverted by a tailoring enzyme SnoN. Furthermore, the 
corresponding gene, snoN, resides outside the cosmid pSnogaori but is present in the 
nogalamycin gene cluster (Siitonen et al., 2016). The structure of nogalamycin F (Fig. 
11: 5, 13), on the other hand, underlies the promiscuity of the GT SnogD, as the sugar 
moiety attached to C1 is deoxy fucose, a neutral sugar. Moreover, the sugar moiety is  
 
 
Figure 12. The nogalamycin gene cluster studied. The major part of the cluster is in the 
cosmid pSnogaori. The rest of the genes are present in the plasmid pIJTZOMLTN, 
marked in white. The genes, which were inactivated from the cosmid pSnogaori in 
different studies are colored black, and the gene snoN, which was studied in IV, is marked 









Figure 13. The expression of the biosynthetic gene cluster of nogalamycin in the 
heterologous host A) The S. albus/pSnogaori + pIJTZOMLTN extract B) The co-elution of 
nogalamycin standard and the product of the strain S. albus/pSnogaori + pIJTZOMLTN 
C) S. nogalater crude extract D) S. albus/pSnogaori products. The numbers refer to the 
compounds (Fig. 11). The figure is modified from Siitonen et al., 2012b. 
Results and Discussion 
48 
  
only attached via an O-glycosidic bond, which gives indications of the C–C bond 
formation. The fact that SnogD attaches a neutral sugar only via an O-glycosidic bond 
indicates that the carbon–carbon bond formation might require a charged group in the 
attached sugar. We later showed that SnogE too exhibits promiscuity, as it can, in 
addition to nogalose, at least add olivose to the C7 position (Fig. 11: 9, 11–12) 
(Siitonen et al., 2016). 
While the new compounds produced by the strain S. albus/pSnogaori are as such 
interesting, the strain also made it possible to create gene inactivation mutants. In the 
first part of the study, we wanted to find out the genes responsible for the sugar 
transfers. The gene inactivation mutants were designed based on a combination of in 
silico studies and what was previously known about the gene cluster (Torkkell et al., 
1997; 2001). Because the structure of nogalamycin is especially interesting due to the 
mode of attachment of the amino sugar moiety, the first genes of interest were the GTs. 
Because one of the three annotated GTs (snogZ) resides in the plasmid and is missing 
from the cosmid, and the strain is still capable of attaching both sugars and creating the 
C–C bond, that gene seems to be redundant. One may speculate that the putative GT 
coded by the gene snogZ could be related to self-resistance, as is shown for example 
for oleandomycin (Cundliffe and Demain, 2010), but there is no experimental proof for 
this hypothesis.  
The gene inactivation mutant missing the gene snogE produces nogalamycinone (Fig 
11: 6) as the main product, implying that SnogE is responsible for the attachment of the 
deoxy sugar at the C7 position. The gene inactivated mutant lacking the gene for 
SnogD produces 3´, 4´-demethoxynogalose-1-hydroxynogalamycinone (Fig. 11: 3), the 
same metabolite that was observed as a minor product of S. albus/pSnogaori, indicating 
that the enzyme is responsible for the attachment of the amino sugar. These gene 
inactivated mutants as well as the strain containing the cosmid pSnogaori also gave an 
indication of the sequence in which the sugar moieties are attached to the backbone. 
First the deoxy sugar is attached to the C7 position and only after that the amino sugar 
at position C1, as none of the compounds had a sugar moiety only at C1 position. 
The new compounds were tested against human topoisomerase I and II, as 
nogalamycin is a known topoisomerase poison (Sim et al., 1997). As nogalamycin F 
(Fig. 11: 5) is structurally more closely related to nogalamycin than 3´, 4´-
demethoxynogalose-1-hydroxynogalamycinone (Fig. 11: 3) it is surprising that the 
former showed less activity against topoisomerase I than the latter. In conclusion, all of 
the novel compounds showed less activity against both topoisomerases than 
nogalamycin.  
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5.2. Unusual Monooxygenase System: SnoaW and SnoaL2 (II) 
Before the amino sugar can be attached to the polyketide at position C1, the carbon has 
to be hydroxylated.  Previously, it had been shown that SnoaL2, a putative 
monooxygenase, is involved in the C1-hydroxylation reaction in nogalamycin 
biosynthesis, but no in vitro activity could be observed at the time (Beinker et al., 
2006; Torkkell et al., 2001). Now the heterologous host expression system made it 
possible to inactivate genes in the cluster to understand the roles of remaining 
unknown gene products, which could clarify the hydroxylation reaction. One of the 
unknown genes was snoaW, which encodes a putative SDR enzyme.  
The two mutant strains with inactivated genes snoaL2 and snoaW gave similar 
chromatogram profiles when extracts of the bacterial cultures were analyzed by HPLC. 
The products contained absorbance maxima at 430 nm, which implied that no hydroxyl 
groups were present at the C1 position. The additional hydroxyl group shifts the 
absorbance maximum to 490 nm, as in the case of 3´, 4´-demethoxynogalose-
nogalamycinone (Fig. 11: 3) due to the change in the conjugated system. The structures 
of the two main products were investigated and verified to be aglycone, 
nogalamycinone (Fig. 11: 6) and a previously unknown product:  nogalamycinone with 
a deoxy sugar attached at the C7 position (Fig. 11: 7).    
The finding implied that both of the enzymes are needed for the hydroxylation 
reaction, as the hydroxylation could not proceed in vivo if one of the components was 
missing. The finding was verified by in vitro reactions using heterologously expressed 
His-tagged proteins (E. coli, TOP10). We demonstrated that the C1-hydroxylation 
reaction proceeds in the presence of NADPH or NADH, the two enzymes, and 
molecular oxygen, but no other components are needed for the reaction. The main 
products of the gene inactivated strains were tested as substrates in the reaction, and 
both could be utilized as substrates. It was nevertheless clear that 3´, 4´-
demethoxynogalose-nogalamycinone (Fig 11:7) is the preferred substrate, because the 
turnover is nearly 100 % within minutes, whereas nogalamycinone (Fig. 11: 6) has 
only a modest turnover (20 %) in an overnight reaction.  
This finding further gave confirmation for the order of the attachment of the sugar 
moieties in vivo, as the sugar is needed at the C7 position for effective turnover. It 
implies that the amino sugar is attached only after the deoxy sugar, which was already 
indicated by the fact that the gene inactivated strain of the deoxy sugar GT, SnogE, 
produces nogalamycinone (Fig. 11: 6) and not menogaril derivatives (Fig. 11: 2). The 
finding is a setback for the idea of synthesizing menogaril derivatives, lacking the 
deoxy sugar but containing the amino sugar moiety, in a heterologous host. Menogaril 
derivatives would be appealing due to the reduced toxicity of menogaril compared to 
nogalamycin (Wiley, 1979). 
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Both NADPH and NADH are possible cosubstrates with the preferred primary 
substrate, 3´, 4´-demethoxynogalose-nogalamycinone (Fig 11:7). However, if the 
substrate nogalamycinone (Fig.11: 6) was utilized, only NADPH led to a reaction. For 
the completion of the reaction, oxygen is needed, but no additional cofactors or metals 
are required. If only SnoaW, without the addition of SnoaL2, is used, it results in a 
non-productive cycle where NAD(P)H is consumed and hydrogen peroxide is formed, 
but no new end product is obtained. Furthermore, it was possible to capture a short-
lived intermediate from a reaction without SnoaL2 and detect it by an HPLC analysis. 
These data led to a model where the primary substrate itself is used as a cosubstrate in 
a similar fashion to flavin being used by flavin-dependent monooxygenases (Fig. 14). 
A similar mechanism was later supported in a study of 1H-3-hydroxy-4-oxoquinaldine 
2, 4-dioxygenase (Hod) from Arthrobacter nitroguajacolicus Rü61a by electron 
paramagnetic studies (Thierbach et al., 2014). 
 
Figure 14. The proposed reaction mechanism for SnoaW/SnoaL2 compared to the flavin-
dependent monooxygenases. A) Flavin-dependent monooxygenase adapted from (Massey, 
1994; Mattevi, 2006; Valton et al., 2008) compared to B) the cosubstrate-independent 
monooxygenase system SnoaW/SnoaL2 (Figure adapted from Siitonen et al., 2012a).  
5.3. Structure of the Glycosyltransferase SnogD (III) 
In the first part of the studies, the roles of GTs responsible for the transfer of both sugar 
moieties of nogalamycin were established (Siitonen et al., 2012b). Because the amino 
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sugar contains the intriguing C–C bond, the GT responsible for the attachment of the 
amino sugar, SnogD, was examined more closely. The 3D structure was solved by 
protein crystallography. The enzyme was found to be a dimer in solution as well as in 
the crystal (Fig. 15A). The crystal structures were obtained both in apo-form and with a 
nucleotide, dUDP, bound. Based on the crystal structures, a model was made with both 
ligands: the donor, TDP-nogalamine, and the acceptor 3´, 4´-demethoxynogalose-1-
hydroxynogalamycinone (Fig. 11: 3, 15B).    
SnogD belongs to the GT1 family and thus has the GT-B fold and utilizes the inverting 
mechanism. Based on the modeled ternary complex, mutants were designed (H301A, 
H25A, H25N). The mutants were examined in vitro in the reverse reaction (Zhang et 
al., 2006a–b), in which the sugar moiety is detached from the backbone and attached to 
NTP. The in vitro reactions were performed using nogalamycin F (Fig. 11: 5) as the 
substrate, which led to the accumulation of 3´, 4´-demethoxynogalose-1-
hydroxynogalamycinone (Fig. 11: 3) as the product. The mutants were also examined 
in vivo by using the gene inactivated strain S. albus/pSnoΔgD supplemented with the 
mutated or wt snogD genes in an additional plasmid. The extracts of these strains were 
examined by HPLC, and the accumulation of amino sugar containing polyketides was 
investigated. These studies confirmed the importance of His25 and His301 for 
catalysis, as the activities of the mutants were reduced significantly. His25 acts as a 
catalytic base in the transfer reaction, whereas His301 binds the diphosphate group of 







Figure 15. A) SnogD crystal structure as a dimer. The important histidines are labeled 
and marked in blue. B) The active site of SnogD in the model of SnogD Michaelis complex 
with acceptor substrate 3 and donor substrate TDP-nogalamine in the active site. The 
calculated electrostatic potential is colored from blue to red (increasing negative charge). 
The figure B) is modified from Claesson et al., 2012.    
The study on SnogD showed that it is responsible for the O–C bond formation of the 
amino sugar but that the C–C bond formation was not likely to be related to the sugar 
attachment by the GT SnogD. The backward reaction did not proceed with the 
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substrate with the intact C–C bond, but was only successful with nogalamycin F 
lacking the C–C bond but with the intact C–O bond. Furthermore, the structure of 
SnogD shows that the enzyme lacks the catalytic groups or cofactors that would 
facilitate the abstraction of the hydrogen, which is likely needed for the C–C bond 
formation.  
5.4. α-KG-Dependent Dioxygenases: SnoK and SnoN (IV) 
5.4.1. Carbon–carbon Bond Formation 
From the first two studies concerning the sugar attachment (Claesson et al., 2012; 
Siitonen et al., 2012b), there was evidence that the GT SnogD is not responsible for the 
C–C bond formation; consequently, there should be another enzyme accountable for it. 
Furthermore, the gene should reside in the cosmid pSnogaori, since compounds with an 
intact C–C bond could be detected in expression studies of S. albus/pSnogaori (Fig. 11: 
4, 12D, 13).  
One of the remaining genes of unknown function was snoK – a gene coding for an α-
KG and Fe2+ dependent dioxygenase. Enzymes belonging to this family perform a wide 
range of reactions (Hausinger, 2004), but this kind of carbocyclization is the first for a 
member of this family. From the unrelated Rieske family an enzyme responsible for a 
similar reaction from the streptorubicin B pathway has been found (Sydor et al., 2011). 
The gene inactivated mutant with missing snoK, S. albus/pSnoΔK, produces two main 
products: nogalamycin K and KO (Fig. 11: 8 and 9), with hypsochromic shifts 
compared to nogalamycin R (Fig. 11: 4) (from 470 nm to 458 nm), slightly changed 
hydrophobic properties based on the retention times by HPLC analyses, and notable 
difference in stability in chloroform. Furthermore, structural elucidation by MS and 
NMR revealed that both compounds lacked the C–C bond. The formation of the C–C 
bond can be observed in vitro when nogalamycin K or KO (Fig. 11: 8 and 9) are used 
as substrates for the heterologously expressed His-tagged SnoK. The reaction can be 
monitored spectrophotometrically as well as with HPLC and MS. If nogalamycin K 
(Fig. 11: 8) is used as a substrate in the in vitro reaction containing α-KG and Fe2+, 
nogalamycin R (Fig. 11: 4) is formed. The reaction requires oxygen, Fe2+ and α-KG. 
The reactions were typically conducted with the addition of L-ascorbate to prevent the 
oxidation state of iron from changing from two to three, but the reaction can also 
proceed in the absence of L-ascorbate. We propose a reaction mechanism where the 
binding of oxygen to Fe2+ leads to a Fe3+-superoxide, which is converted to a cyclic 
ferryl-bridged peroxo species after a nucleophilic attack by the carbonyl carbon of α-
KG. The cleavage of the oxygen–oxygen bond and decarboxylation of α-KG leads to 
the production of succinate, carbon dioxide and the reactive Fe4+=O species. The steps 
until this point are typical for α-KG and Fe2+ dependent oxygenases. We propose that 
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the reaction continues by abstraction of the H5´´-atom by the Fe4+=O species. This 
creates a substrate radical. Finally, the C–C bond is formed by the attack of the C2 to 
the radical center (Fig. 16).  
5.4.2. Stereochemistry of C4´´  
The stereochemical difference between nogalamycin R (Fig. 11: 4) and nogalamycin 
(Fig. 11: 1) resides at the C4´´ position, which was previously speculated to arise from 
gene products expressed by the heterologous host (Siitonen et al., 2012b). The 
stereochemical change was proven to be the action of another α-KG and Fe2+ 
dependent enzyme, SnoN (Siitonen et al., 2016). The remaining genes outside the 
cosmid pSnogaori included genes coding for methyltransferases (snogY, snogM), for 
resistance (snorO), and two genes of unknown function (snoT, snoN), which encode a 
Rieske-type dioxygenase SnoT and an α-KG and Fe2+ dependent dioxygenase SnoN, 
respectively. 
The unknown gene snoN, which based on the sequence analysis produces an α-KG and 
Fe2+ dependent dioxygenase, was introduced to the heterologous host containing the 
cosmid pSnogaori. In this strain, new products arose with the identical stereochemistry 
of the C4´´ position to that of nogalamycin based on the coupling constant of the 
hydrogens attached to the C4´´ (J3´´, 4´´: 10.5 1, J3´ ,́ 4´´: 10.6 10, J3´´, 4´´: 10.5 12). The 
strains without the addition of snoN produce compounds with significantly smaller 
coupling constants. This demonstrated in vivo that the epimerase changing the 
stereochemistry of the C4´´ is SnoN and that the product nogalamycin R (Fig. 11: 4) 
produced by the strain S. albus/pSnogaori may indeed be a true intermediate of the 
pathway, and it is not likely to originate from the interference of genes from the 
heterologous host S. albus, as speculated earlier (Siitonen et al., 2012b).  
 
The gene was also expressed in a heterologous host (E. coli, TOP10) as a His-tagged 
protein for in vitro characterization. It appears that, instead of generating the biological 
reaction, the purified SnoN generates compounds with smaller masses when 
nogalamycin R (Fig. 11: 4), nogalamycin RO (Fig. 11: 11), nogalamycin K (Fig. 11: 8) 
or nogalamycin KO (Fig. 11: 9) are used as substrates. When nogalamycin RO (Fig. 
11: 11) is used as a substrate, instable intermediates are formed, which are readily 
converted to a stable end product. The structure of this product was solved by MS and 
NMR, and it shows that the amino sugar has been broken into a ketone group attached 
to the backbone by a C–C bond (Fig. 11: 13). The extensive degradation of the amino 
sugar portion of the substrate is proposed to arise from the appearance of radicals in the 
reaction. Without the physiological context, the radicals are scavenged by the substrate, 
thus breaking the compound. A similar enzyme CarC from the pathway of carbapenem 
has been proposed to act in a similar manner (Chang et al., 2014), but there are 
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differences in the proposed reaction mechanisms. In the case of CarC, the enzyme is 




























Figure 16. The proposed reaction mechanisms of SnoK and SnoN. Figure modified from 
Siitonen et al., 2016. 
CarC achieves stereoinversion by creating a Fe4+-oxo intermediate, which abstracts 
hydrogens from C5. Subsequently, the tyrosine Y165 donates the hydrogen to the other 
side of the substrate, creating an epimer of the original compound (Chang et al., 2014). 
Based on the CarC structure and mechanism, SnoN mutants were designed (W64F, 
Y74F and W180F). None of the mutants diminished the consumption of the used 
substrate, nogalamycin K (Fig. 11: 8, 17). Furthermore, these amino acids are not as 
well positioned in relation to the substrate as in CarC. We therefore suggest that amino 
acid radicals are not necessarily involved in the reaction, as in the case of CarC (Chang 
et al., 2014). Further evidence for the difference between the CarC and SnoN reactions 
is given by the usage of α-KG. We show that SnoN utilizes one α-KG per two substrate 
molecules, suggesting that SnoN needs an additional component to donate a hydrogen 
atom back to the substrate, while SnoN is only responsible for the abstraction of the 
hydrogen (Fig. 16). 










Figure 17. The binding of the primary substrates to the enzymes SnoK and SnoN. A) 
SnoK with nogalamycin K modelled into the active site with important amino acids shown 
and the activities of the mutants studied visualized. B) SnoN in complex with nogalamycin 
RO with important amino acids shown and the activities of the mutants studied visualized. 
Legend: boiled, heat inactivated enzyme; -α-KG, control reaction without α-KG; WT, 
wild type enzyme. Figure adapted from Siitonen et al., 2016. 
5.4.3. Comparison of SnoK and SnoN 
The crystal structures of both, SnoK and SnoN were solved. Both are in complex with 
α-KG and mononuclear iron. Furthermore, a complex of SnoN with the substrate 
nogalamycin RO (Fig11: 11) was obtained. The main differences between SnoN and 
SnoK are highlighted in figure 17; overall, the structures are very similar. The figure 
shows SnoK with modeled nogalamycin K (Fig. 11: 8) in the active site (Fig. 17A) and 
SnoN with bound nogalamycin RO (Fig. 11: 11, 17B). The most important difference 
is in the alignment of the substrate in the active site. The positioning of the amino 
sugar moiety in front of the iron is different. In SnoK, the residues Ser104 and Asp106 
bring the substrate deep into the cleft of the enzyme. The carbons C5´´ of the sugar and 
C2 of the aglycone are positioned next to the iron, facilitating carbocyclization. The 
importance of the residue in substrate alignment was demonstrated by the mutants 
D106A/N, which both abolished the activity of SnoK (Fig. 17A). In SnoN, the 
corresponding residues are the longer residues Lys110 and Glu112, which prevent the 
substrate from going as deep in the cleft as in the case of SnoK. One hypothesis was 
that, if Lys is replaced by a shorter residue, it might compromise the catalytic activity 
of SnoN, but the mutant K110S did not considerably lower the activity (Fig. 17). 
Finally, two more notable differences affect the positioning of the primary substrate in 
the active site; the loop between β7 and β8 is six amino acids longer in SnoK than in 
SnoN, whereas the C-terminal section is seven amino acids longer in SnoN than SnoK 
(Fig 17). 
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6. CONCLUDING REMARKS AND FUTURE PERSPECTIVE 
Within the scope of this thesis, the functions of six previously unknown or unverified 
gene products from the nogalamycin biosynthesis were established. We now 
understand how C1-hydroxylation of the aglycone is achieved, what proteins are 
responsible for the attachment of both sugar moieties, and what proteins are 
responsible for the C–C bond formation as well as the C4´´ epimerization.  
The important prerequisite for this advancement was that we were able to produce 
nogalamycin in the heterologous host S. albus. The study provided novel enzyme 
mechanisms, which included the discovery of an unusual two-component 
monooxygenase system, and two α-KG and iron dependent non-heme oxygenases, 
which catalyze unconventional reactions. During the course of the study, we solved the 
structures of three enzymes. The SnogD GT provides an important progression in 
structural biology in the field of unusual sugar biosynthesis. The other two enzymes 
were two homologous α-KG and iron dependent non-heme oxygenases. Despite the 
diverse chemistries that these enzymes catalyze in comparison to their canonical family 
members, the structures proved to be very similar to those more conventional members 
of the family.  
One fruitful and feasible future prospect is the possibility to make mutagenesis to 
SnoK and SnoN mutants, as they have very similar structures and somewhat similar 
sequences (38 % identity). The goal could be to alter the activity of both towards each 
other – or to change the site of the reaction, epimerization, or C–C bond formation. The 
studies now show that one important factor in the different chemistries they utilize is 
the orientation of the substrate in the active site; changing the cavity and the orientation 
could change the chemistries or the site of the reaction. Additionally, further work is 
required to elucidate the details of the SnoN reaction in vitro and the causes that lead to 
the degradation of the substrate. Even though we have extensively studied different 
possibilities regarding the SnoN in vitro reaction, it is still possible that future results 
will shed light on the unknown missing component of the SnoN reaction and enable in 
vitro epimerization of the substrate.  
The advances in understanding the biosynthesis of unusual sugars in a broader sense 
has taken important steps forward in the past years, as was elaborated in the Literature 
Review part of this thesis. Not only knowledge on how the sugars are generated in 
nature but also knowledge and new techniques on how to create even more diverse 
sugars as well as how to utilize them as parts of novel compounds have been discussed, 
and the progression is clear. Nevertheless, the long-awaited breakthrough in achieving 
novel drugs produced in the ways presented in the thesis has not yet been made. 
However, with the growing need for finding novel antibiotics and other useful drugs, 
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the possibility that more effort is made in this branch of biochemistry may one day 
convert basic science into useful applications. The findings of this thesis could also be 
used in the long-term in creating novel drugs. I would like to see enzymes and genes 
that we have studied used as components in elegant machineries when novel 
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